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[57] ABSTRACT 
The invention provides method and kits for detecting a 
metallic cation in a sample of a body fluid. The preferred 
method and kits include the use of at least two different types 
of antibodies having different specificities. In the preferred 
method, the sample of body fluid can be contacted with an 
effective amount of a capture antibody specific for a natu-
rally occurring polypeptide that can bind the metallic cation 
to form a first antigen-antibody complex. An effective 
amount of an antibody specific for an epitope on a metallic 
cation-naturally occurring polypeptide complex or an anti-
body specific for a metallic cation is added to the first 
antigen-antibody complex to form a second antigen-anti-
body complex. The amount of the metallic cation in the 
sample of body fluid is determined by detecting the amount 
of the second antigen-antibody complex. 
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MONOCLONAL ANTIBODY ASSAY AND KIT 
FOR DETECTING METAL CATIONS IN 
BODY FLUIDS 
2 
assays are not generally convenient and rapid enough to use 
for a widespread screening program. 
Thus, there is a need for a reliable and rapid screening 
and/or diagnostic assay for the presence of lead or other 
BACKGROUND OF THE INVENTION 
The burdens that exposure to lead and other metal cations 
places on society and individuals are massive when one 
considers the amount of money required for health care for 
those who develop metal cation-induced mental and physi-
5 metallic cations in animals and the environment. In addition 
there is a need for an immunoassay for the quantitative 
detection of lead and lead-ALAD in blood. There is also a 
need for a rapid screening assay in a kit to determine metal 
cation concentrations in fluids derived from humans, ani-
10 mals or the environment. 
cal disabilities, and the loss of the productive contributions 
that these individuals might otherwise make. For example, 
lead exposure can cause acute or chronic manifestations 
depending on the amount of lead to which a person has been 
exposed, and the duration of exposure. Acute exposure to 15 
lead most often leads to intestinal colic, while chronic 
exposure can result in various neurological symptoms, rang-
ing from encephalopathy to psychological deficits, such as 
decreased intelligence and behavioral disturbances. Other 
metallic cations, such as mercury and cadmium, can also 20 
have adverse effects on nervous, reproductive and immuno-
logical systems. 
SUMMARY OF THE INVENTION 
The invention provides methods and kits for detecting a 
metallic cation in a sample of a body fluid of an animal. The 
preferred methods and kits can involve the use of at least two 
antibodies having different specificities. These antibodies 
fall into two general types with the second including several 
subtypes. In a first alternative, the method of the invention 
can be conducted by contacting the sample of body fluid 
with an effective amount of a first type of antibody, which is 
One of the real tragedies in this situation is that, for the 
most part, this situation is preventable. If convenient, inex-
pensive, and reliable screening methods existed, they could 
be applied to identifying individuals at risk and to localizing 
environmental sources of lead and other metal cations before 
irreversible health effects occurs. 
Most of the methods, such as atomic absorption spec-
trometry and anodic stripping voltametry, have been 
directed toward detection of metal cations, including lead, in 
blood. However, these procedures utilize expensive, special-
ized equipment that requires highly trained personnel for 
proper operation, thus making their use in widespread 
screening programs difficult, if not impossible. 
specific for a naturally occurring polypeptide that can bind 
the metallic cation to form a first antigen-antibody complex. 
The first antibody in this step is functioning as the capture 
25 antibody. A second type of antibody is added in an effective 
amount to the first antigen-antibody complex to form a 
second antigen-antibody complex. The second antibody is 
(1) specific for an epitope on a metallic cation-naturally 
occurring polypeptide complex and not substantiaily cross-
30 reactive with the naturally occurring polypeptide alone, or 
(2) specific for a metallic cation or (3) specific for a 
combination of a complexed metallic cation and its coordi-
nation site in a metallic cation-naturally occurring polypep-
tide complex. The metallic cation in the sample of the body 
35 fluid is detected by determining the amount of the second 
antigen-antibody complex. As an alternative, other parameters which might serve as 
reliable indicators of blood metal cation contamination have 
been sought. Those which have been identified for lead 
include an increase in erythrocyte protoporphyrin (S. 40 
Piomelle, Low Level Lead Exposure, H. Needleman, editor, 
Raven Russ, NY, pp. 67-74 (1980», a decrease in o-ami-
nolevulinic acid dehydratase (ALAD) enzyme activity (S. 
Hemberg et al., Lancet, 1:63-66 (1970», and a decrease in 
heme synthetase activity (0. Wada et al., Ind. Health, 45 
10:84-92 (1972». Of these, only the increase in erythrocyte 
protoporphyrin (EP) has been exploited for use as a screen-
ing method to detect the presence of lead in blood. The 
major difficulty with this system is that measurement of EP 
This first alternative of the method of the invention can 
also be modified by use of the first and second types of 
antibodies in reverse order. In this modification the second 
antibody functions as the capture antibody to capture the 
metallic cation-naturally occurring polypeptide complex. 
In a second alternative, the method of the invention can be 
conducted by contacting a sample of the body fluid with one 
of the sub-types of the above-described second type of 
antibody to form a first antigen-antibody complex. The 
is not sensitive enough for accurate correlation with a blood 50 
lead concentration below 25 ~g/dl, which is 2.5 times above 
the limit recently defined by CDC as the "safe" level oflead 
second antibody in this step functions as the capture anti-
body. The same or another subtype of the second type of 
antibody is then added to the first antigen-antibody complex 
to form a second antigen-antibody complex. If the same 
subtype is used, the complex will contain multiple epitopes 
of the same structure to enable multiple antibody binding. If 
the complex does not contain such epitopes, different sub-
types of second type of antibody will be used. The metallic 
in blood. (L. Alessio et al., British 1. Ind. Med., 38:262-267 
(1981).) 
ALAD is a zinc-containing enzyme, and inhibition of its 
enzymatic activity is thought to result from displacement of 
zinc by metal cations including lead. (E. Jaffe et al., Bioi. 
Trace Element Res., 28:223-232 (1991).) It is generally felt 
that a decrease in ALAD activity is the first measurable 
effect of lead contamination and is the most sensitive mea-
sure of lead toxicity (Hernberg et aI., cited supra.). A 
decrease in ALAD has been implicated in the pathogenesis 
of lead poisoning and, thus, may also serve as a reliable 
indicator of clinical status of a patient exposed to lead or 
other heavy metals. Astrin et al., Ann Ny Acad. Sci., 514:23 
(1987). The difficultly with using this parameter for devel-
opment of a practical assay for blood lead is that enzyme 
55 cation in the sample of body fluid is detected by determining 
the amount of the second antigen-antibody complex. 
Assays for detecting a metallic cation in a body fluid can 
also involve the use of a single type of antibody. The single 
type of antibody has specificity for an epitope on a naturally 
60 occurring polypeptide that binds at least two metallic cat-
ions. In this version of the assay, a sample of body fluid is 
contacted with an effective amount of a first antibody 
specific for (1) an epitope or (2) a combination of a com-
plexed metal cation and its complexation site on a metallic 
65 cation/naturally occurring polypeptide complex that binds at 
least two metallic cations to form a first antigen-antibody 
complex. An effective amount of a second antibody, which 
5,532,136 
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is of the same type as the first antibody but is not necessarily 
the same thing, is added to form a second antigen-antibody 
complex. The metallic cation in the sample is detected by 
determining the amount of the second antigen-antibody 
complex. The first and second antibodies can be specific for 5 
the same or different epitopes. 
In a further version, a method for detecting a metallic 
cation in a sample of body fluid combines an antibody 
binding assay with an enzyme assay. In that method, a 
sample of body fluid containing the metallic cation is 10 
contacted with an effective amount of an antibody specific 
for an epitope on a metallic cation/enzyme complex or an 
epitope on a naturally occurring polypeptide to form an 
antigen-antibody complex. The metallic cation is then 
removed from the antigen-antibody complex, preferably by 
stripping with a chelator or by substitution with a different 15 
metallic cation. The enzyme activity is restored upon 
removal of the metallic cation and, preferably, by replace-
ment of the metallic cations with a different metallic cation, 
such as the enzyme's natural cofactor. The metallic cation in 
the sample is detected by assaying the restored enzyme 20 
activity. 
Another method of the invention provides for a determi-
nation of whether the animal has been acutely or chronically 
exposed to the metallic cation. The steps of the method 25 
include detecting the amount of the metallic cation bound to 
a first naturally occurring polypeptide, detecting the amount 
of the metallic cation bound to one or more, preferably two 
or three, other naturally occurring polypeptides, and com-
paring the amount of the antibody bound to the first polypep- 30 
tide to that of the other polypeptides to determine if the 
exposure is acute or chronic. The preferred detection method 
is that described in the Detailed Description of the Invention. 
An antibody (the first type of antibody) specific for a 
naturally occurring polypeptide that binds the metallic cat- 35 
ion can serve to capture the naturally occurring polypeptide 
from the sample of body fluid or, in an alternate version can 
also serve as a detection antibody when the capture antibody 
is the second type of antibody. The antibody preferably is a 
monoclonal antibody and recognizes and binds to the natu- 40 
rally occurring polypeptide whethcr or not it is complexed 
with one or more metallic cations. The monoclonal antibody 
also preferably binds to the naturally occurring polypeptide 
in the body fluid in less than about 10 minutes, and with a 
disassociation constant of about 10-4 to 10-13• The most 45 
preferred antibody is a monoclonal antibody specific for 
ALAD. 
An antibody (the second type of antibody) (1) specific for 
4 
at the metal coordination site. The preferred antibody is a 
monoclonal antibody specific for a metallic cation. The 
especially preferred antibody is a monoclonal antibody 
specific for a toxic metallic cation, such as lead, mercury, 
cadmium, and gallium. 
The method is preferably conducted with one of the 
antibodies immobilized on a substrate and the other antibody 
labelled with a detectable agent. Antibodies can be immo-
bilized to a variety of solid substrates by known methods. 
Suitable solid substrates include materials having a mem-
brane or coating supported by or attached to sticks, cups, flat 
packs, or other solid supports. Other solid substrates include 
cell culture plates, ELISA plates, tubes, and polymeric 
membranes. The preferred solid substrate is a stick coated 
with a polymeric membrane. The detectable agent functions 
to allow detection of the second antigen-antibody complex 
and includes fluorochromes, radioactive labels, biotin and 
enzymes. The preferred detectable agent is an enzyme, and 
the especially preferred detectable agent is horseradish per-
oxidase. 
The amount of the second antigen-antibody complex 
detected is preferably proportional to the amount of metallic 
cation present in the sample of body fluid. The amount ofthe 
metallic cation present in a sample of body fluid can be 
determined by correlating the amount of the second antigen-
antibody complex detected in the sample with that detected 
for standard amounts of the metallic cation-naturally occur-
ring polypeptide complex. Standard solutions of the same 
amount of a purified naturally occurring polypeptide that 
binds metallic cation are mixed with different concentrations 
of the metallic cations ranging from 0.5 ].lg/dl to 50 ].lg/dl. 
The standard curve generated can be used to quantitate the 
amount of metallic cation in a sample. Alternatively, the 
standard solutions can be used to measure the disassociation 
constant of antibodies. 
The invention also provides a preferred kit containing 
eithertwo types of antibodies or one or more versions of the 
second type of antibody for detecting a metallic cation in a 
sample of body fluid. The kit preferably contains the first 
type of antibody and the second type of antibody. Alterna-
tively, the kit can also contain a first antibody and a second 
antibody wherein both are specific for an epitope on a 
metallic cation/naturally occurring polypeptide that binds at 
least two metallic cations. A kit can also contain an antibody 
specific for a naturally occurring enzyme that binds the 
metallic cation or an antibody specific for a metallic cation 
enzyme complex, and substrates for measuring the enzyme 
activity. 
One of the antibodies in the kit is preferably immobilized 
and the other antibody is labelled with a detectable agent. 
When the detectable agent is an enzyme, a means for 
detecting the detectable agent is supplied with the kit. The 
preferred means for detecting the detectable agent is an 
an epitope on a metallic cation-naturally occurring polypep-
tide complex, or (2) specific for a mctallic cation or (3) 50 
specific for a combination of a complexed metallic cation 
and its coordination site in a metallic cation-naturally occur-
ring polypeptide complex functions to allow detection of the 
amount of metallic cation present in the sample of body fluid 
55 enzyme substrate that changes color upon contact with the 
enzyme. The kit also optionally includes standard amounts 
of metallic cation-naturally occurring polypeptide com-
plexes andlor a chart with visual representations of the 
amount of colored product corresponding to the standard 
or, in an alternate version, can also serve as a capture 
antibody. An antibody can be specific for the metallic cation 
portion or the naturally occurring polypeptide portion or the 
combination of the metallic cation and polypeptide metal 
complexation site of the metallic cation-naturally occurring 
polypeptide complex. When the antibody is specific for the 
naturally occurring polypeptide portion, it does not substan-
tially cross-react with the epitopes on the naturally occurring 
polypeptide not complexed with the metallic cation (Le., 
alone). When the antibody is specific for the metallic cation, 
60 amounts of the metallic cation-naturally occurring polypep-
tide complexes andlor can be quantified spectrophotometri-
cally. 
it binds the metallic cation whether or not complexed with 65 
a naturally occurring polypeptide. When the antibody is 
specific for the combination, it only binds with the complex 
The kits provide a rapid diagnostic andlor screening 
method for determining contamination of animals with 
metallic cations, especially toxic metallic cations. The kits, 
as disclosed herein, are especially advantageous because 
they provide a simple and inexpensive method to measure a 
5,532,136 
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large number of samples of body fluid for metal ion con-
tamination. The kits, as disclosed herein, are also very 
versatile in that the kit can be designed to be quantitative or 
qualitative, or for use in the field or in the laboratory. 
DETAILED DESCRIPTION OF THE DRAWINGS 
FIG. 1 shows inhibition of binding of mAb 4AlO and 
mAb lFlO to immobilized BSA-glutathione-HgCI by 
soluble mercuric chloride. 
FIG. 2 shows detection of mercury in the EPA Quality 
Control sample by ELISA. 
FIG. 3 shows a comparison of mercury detection by 
ELISA and atomic absorption. 
6 
essential for the activity of the naturally occurring polypep-
tide. The naturally occurring polypeptides can function as 
indicators of the presence of and the amount of the metallic 
cation in a body fluid, such as blood. In the case of some 
5 metallic cations, the naturally occurring polypeptide can 
serve to concentrate the metallic cation from the liquid 
portion of the blood serum. In addition, the binding of some 
metallic cations to the polypeptide can inactivate the func-
tion of the polypeptide. The inactive naturally occurring 
10 proteins can contribute to pathogenesis associated with 
exposure to metallic cations and serve as an indication of the 
clinical status of the animal. A naturally occurring polypep-
tide is one that is formed by the animal and is usually present 
in sufficient concentrations to be detected in the body fluid. 
FIG. 4 shows inhibition of binding of mAb 1 C3 and mAb 15 
14FIl to immobilized BSA-glutathione Pb+2 by soluble lead 
acetate. 
The naturally occurring polypeptide is capable of binding 
at least one, and preferably more than one different metallic 
cations to form a metallic cation-naturally occurring 
polypeptide complex. A naturally occurring polypeptide can 
normally contain a metallic cation cofactor that can then be 
FIG. 5 shows a Western blot of metal-contaminated red 
celllysates. Metal-containing proteins were detected with an 
antibody specific for lead cations. Hemoglobin is shown at 
the arrow. Lane 1 represents molecular weight standards; 
Lane 2: red cell lysate depleted of lead; Lane 3: red cell 
lysate with 55 ~g/dl lead; Lane 4: red cell lysate with 20 
~g/dllead; and Lane 5: red cell lysate with 5 ~g/dllead. 
DETAILED DESCRIPTION OF THE 
INVENTION 
Methods and kits provided for in the invention allow for 
the detection of metallic cations in a sample of body fluid. 
The preferred method and kit involve the use of at least two 
antibodies having different specificities, i.e., a selection from 
the two types of antibodies. One type of antibody is specific 
for a naturally occurring polypeptide that binds metallic 
cations present in the body fluid. The other type of antibody 
is composed of three subtypes of differing specifications. 
The first subtype is specific for an epitope on a metallic 
cation-naturally occurring polypeptide complex. The second 
subtype is a specific for a metallic cation. The third subtype 
20 displaced by binding to different metallic cation. For 
example, a naturally occurring polypeptide can have Zn+2 
cations as the native cofactor but also can bind to lead, 
mercury and cadmium cations which replace the Zn+2 cat-
ions. Replacement of the native cofactor metallic cation with 
25 another metal cation can lead to inactivation of the function 
of the polypeptide. For example, replacement of Zn+2 in 
ALAD by Pb+2 results in an inactivation of ALAD enzyme 
activity. 
Preferably, the naturally occurring polypeptide can bind 
30 an amount of the metallic cation that is proportional to the 
amount of metallic cation in a sample of body fluid. The 
naturally occurring polypeptide coordinates or binds the 
metallic cation with sufficient strength so that the metallic 
cation is retained by the polypeptide even though the 
35 polypeptide is washed with buffer solution several times. 
Preferably, the naturally occurring polypeptide and the 
metallic cation formed a coordinate covalent bond. A natu-
rally occurring polypeptide binds or coordinates with the 
metallic cation preferably with an disassociation constant of 
40 about 10-5 to 10-10. is a specific for a combination of a complexed metallic 
cation and its complexation site in a metallic cation-natu-
rally occurring polypeptide complex. The antibody specific 
for metallic cation-naturally occurring polypeptide complex 
can be specific for either the metallic cation portion or the 
naturally occurring polypeptide portion of the complex. The 45 
two antibodies are combined in a preferred method that 
allows the detection of the metallic cation in a body fluid by 
determining the amount of the metallic cation bound to a 
naturally occurring polypeptide present in the body fluid. 
The metallic cations bound or coordinated by a naturally 
occurring polypeptide include cations of alkaline metals, 
transition metals, i.e., those elements in the periodic table 
with their outer most electrons in d" orbitals, the Group IlIa 
metal!metalloids (B, AI, Ga, In, and TJ), the Group IVa 
metal/metalloids (Si, Ge, S, and Pb), the Group Va metal! 
metalloids (As, Sb and Bi). The metallic cation can be 
monovalent or multivalent, but is preferably divalent and 
can be bound to another organic moiety, e.g., methylmer-
cury. More preferably, the metallic cation is a toxic metallic 
cation known to have toxic effects on humans and other 
A. Antibodies to Naturally Occurring Polypeptides That Can 50 
Bind the Metallic Cation 
Antibodies having specificity for a naturally occurring 
polypeptide that can bind a metallic cation are useful in 
method and kits of the invention. Preferably, the antibody is 
a mammalian IgG, IgA or IgM antibody, and more prefer-
ably the antibody is a monoclonal antibody. A monoclonal 
antibody specific for a naturally occurring polypeptide, 
preferably has a disassociation constant about 10-5 to 10-10. 
A disassociation constant is the ratio of the multiplication 
product of the concentrations of all reactants to the multi-
plication product of the concentrations of all products found 
in an equilibrium mixture, as described by the method of 
Friguet et al., 1. Immunol. Methods, 77:305 (1985). 
Many naturally occurring polypeptides found in animals 
are capable of binding one or more metallic cations. These 
naturally occurring polypeptides are also known as metal-
loproteins. A metallic cation typically serves as a cofactor 
animals, as described in Handbook on the Toxicology of 
Metals, 2nd Edition, Eds: Friberg, Nordberg, Vouk, Elsevier, 
Amsterdam (1986). Toxic metallic cations include those that 
55 bind to sulfhydryl containing polypeptides including but not 
limited to lead, mercury, cadmium, copper, methylmercury, 
and others that do not bind sulfhydryl groups. A naturally 
occurring polypeptide is preferably capable of binding or 
coordinating with lead, mercury, methylmercury, cadmium 
60 and/or gallium cations. 
Suitable examples of naturally occurring polypeptides 
that bind metallic cations include o-aminolevulinic acid 
dehydratase (ALAD), hemoglobin (Baltrop et al., Experien-
tia, 28:76 (1972», heme synthetase (Erikson, Scand. 1. 
65 Cline. Lab. Investigations, 4:55-62 (1952», coproporphy-
rinogen decarboxylase (Goldberg et al., Blood, 11 :821 
(1956», ALA-synthetase (Drussel et al., Biochem. 1., 63:72 
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(1956)), human serum albumin, glutathione, pyrimidine 5' 
nucleotidase, protein kinase C, and metallothioneins (M. 
Karin, Cell, 41:9 (1985)). The preferred naturally occurring 
polypeptide that binds metallic cations is D-aminolevulinic 
acid dehydratase (ALAD). 
The naturally occurring polypeptide that binds metallic 
cations can be isolated from animal species, including 
humans, cows, fish, and other vertebrates. The naturally 
occurring polypeptide is isolated, purified, and used as an 
immunogen to form antibodies. Purification methods for 
polypeptides that bind metallic cations from body fluids are 
standard methods, including ammonium sulfate precipita-
tion and chromatography, such as ion exchange, affinity and 
HPLC chromatography. 
A naturally occurring polypeptide that binds the metallic 
cations is used as an immunogen to form polyclonal and 
monoclonal antibodies. The immunogen can contain a single 
polypeptide or a plurality of polypeptides such as found in 
a red cell lysate or serum. The immunogen can also be a 
naturally occurring polypeptide complexed with one or more 
metallic cations. Typically an animal that is a different 
species than that from which the naturally occurring 
polypeptide is isolated is immunized with the purified 
polypeptide. The immunogen is administered parenterally, 
most often, either subcutaneously or intraperitoneally in an 
adjuvant. Administration of the immunogen is repeated 
periodically and preferably for at least four injections. After 
repeated immunizations, polyclonal serum can be harvested 
from the animal. 
Preparation of monoclonal antibodies is achieved by the 
standard technique, as described in Antibodies: A Labora-
tory Manual, Harlow & Lane; Cold Spring Harbor (1988). 
Briefly, spleens are harvested from animals immunized with 
the immunogen as described above. Spleen cells are sepa-
rated and fused with the immortal myeloma cells using 
polyethylene glycol. The fused hybridoma cells are selected 
and cultured in vitro. The hybridoma cell culture fluids are 
tested for the presence of hybridoma antibodies having a 
certain specificity. 
The selection technique for identifying the appropriate 
first type monoclonal antibody is an important aspect for 
determining the immunospecificity desired according to the 
invention. The hybridoma cells culture fluids are tested for 
the presence of antibodies specific for the naturally occur-
ring polypeptide with an ELISA conducted by standard 
methods. 
Additional screening methods can also be employed to 
further select the monoclonal antibody having the desired 
specificity. One or more of these screening methods can be 
employed to select a monoclonal antibody having a particu-
lar specificity. Those additional screening methods include 
screening for monoclonal antibodies that can also bind to the 
naturally occurring polypeptide when it is a part of a metallic 
cation-naturally occurring polypeptide complex. Another 
preferred monoclonal antibody recognizes and binds the 
naturally occurring polypeptide whether or not it is com-
plexed with one or more metallic cations. In addition, the 
hybridoma cell culture fluid can also be selected for mono-
clonal antibodies that are specific for the biologically active 
form of the naturally occurring polypeptide. Alternatively 
and optionally, a monoclonal antibody specific for a natu-
rally occurring polypeptide that binds the metallic cation can 
be screened for specificity for the naturally occurring 
polypeptide from several different species of animals. 
The selection for a monoclonal antibody specific for 
biologically active forms of the naturally occurring polypep-
tide can be accomplished by contacting the hybridoma cell 
8 
culture fluid containing monoclonal antibodies with the 
naturally occurring polypeptide to form an antigen-antibody 
complex, separating the antigen-antibody complex, and then 
assaying the antigen-antibody complex for functional activ-
5 ity. For example, if the naturally occurring polypeptide is an 
enzyme, the antigen-antibody complex can be assayed for 
enzymatic activity. 
Suitable monoclonal antibodies are those specific for 
ALAD, hemoglobin, glutathione, human serum albumin, 
10 and the metallothioneins. The preferred monoclonal anti-
body is specific for ALAD. Suitable polyclonal antibodies 
are those to human serum. Some of these antibodies are 
commercially available. 
In the preferred version, monoclonal antibodies to the 
15 naturally occurring polypeptideALAD are formed. ALAD is 
an enzyme that is known to bind Zn+2 cations as its native 
metallic cation cofactor, however, the enzyme is also known 
to bind or coordinate with lead, mercury, cadmium, or 
copper as well. Bernard & Lauwerys, Ann. NY Acad. Sci., 
20 51:41--47 (1987). BovineALAD is purified from erythrocyte 
cell lysates, as described by the method of Fujita et al., 
Biochem. Biophys. Acta, 678:39-50 (1981) using ammo-
nium sulphate precipitation and heat treatment followed by 
DEAE and ultragel ACA34 chromatography. An effective 
25 amount of purified bovine liver ALAD is injected with 
adjuvant into mice. Polyclonal serum can be harvested from 
the mice at this point and the presence of ALAD-specific 
antibodies is monitored by ELISA. The spleen is fused to 
form hybridoma cell lines. Monoclonal antibodies specific 
30 for ALAD, whether or not complexed with lead, are 
selected. Monoclonal antibodies are further selected for 
specificity for the biologically active form of ALAD by 
assaying ALAD monoclonal antibody complexes for ALAD 
enzyme activity by the method of Tsukomoto et al., Bio-
35 chem. Biophys. ACTA, 570:167-178 (1979). The preferred 
monoclonal antibody specific for bovine ALAD also recog-
nizes and binds to human ALAD. 
The invention also provides a method for identifying 
naturally occurring polypeptides that can bind metallic cat-
40 ions present in body fluids. The method involves using a 
Western blot assay with monoclonal antibodies specific for 
metallic cations. Samples of a body fluid from an animal are 
treated so that any cells in the body fluid are lysed. The 
sample of the body fluid is then incubated with various 
45 concentrations of a metallic cations, preferably the concen-
trations range from 0.5 J.lg/dl to 50 J.lg/dl of the metallic 
cation or can be obtained from animals dosed experimen-
tally with varying amounts of metallic cations. The metallic 
cation-treated sample is then subjected to electrophoresis. 
50 The proteins separated by electrophoresis are transferred to 
a nitrocellulose membrane. The separated proteins on the 
nitrocellulose membrane are then incubated with mono-
clonal antibodies labelled with a detectable agent and spe-
cific for the metallic cation added to the initial solution. 
55 Separated proteins binding to the monoclonal antibodies 
specific for the metallic cation are identified by detecting the 
detectable agent. The polypeptides that have bound the 
metallic cation are identified by molecular weight and can be 
eluted from an electrophoresis gel run in parallel. The 
60 polypeptides that bind metallic cations can be identified by 
comparison to a panel of known polypeptides that bind 
metallic cations to help identify the polypeptide. Compari-
son methods can include Western blots, PAGE, HPLC, other 
chromatography. Any new polypeptides identified as bind-
65 ing to metallic cations can be further characterized by 
standard methods for amino acid analysis and enzyme 
activity. 
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The method allows the identification and characterization 
of naturally occuning polypeptides that can bind metallic 
cations and also allows the identification of naturally occur-
ring polypeptides that can bind metallic cations present at 
very low concentrations. 
B. Antibodies that Can Detect the Presence of the Metallic 
Cation 
Antibodies of the second type are useful in the methods 
and kits of the invention. The antibodies are preferably 
mammalian antibodies of the IgG, IgA and IgM class, and 
more preferably are monoclonal antibodies. One version of 
this type of antibody is specific for an epitope either as the 
metallic cation portion or as the naturally occuning polypep-
tide portion of the metallic cation-naturally occuning 
polypeptide complex. An epitope on the metallic cation-
naturally occuning polypeptide complex can be (1) the 
metallic cation or (2) peptide epitope or (3) the metallic 
cation-peptide coordinate epitope recognized only when the 
naturally occuning polypeptide is complexed with the 
metallic cation. The antibody can also be specific for a 
metallic cation whether or not bound to a naturally occuning 
polypeptide. The preferred monoclonal antibodies are spe-
cific for a metallic cation and also, more preferably, bind to 
and recognize the metallic cation portion of a metallic 
cation-naturally occuning polypeptide complex. The mono-
clonal antibodies are specific for an epitope only found on a 
metallic cation-naturally occuning polypeptide complex, 
Le., the monoclonal antibody does not substantially cross-
react with the naturally occuning polypeptide not com-
plexed with the metallic cation (i.c., alone). 
Monoclonal antibodies specific for metallic cations or for 
a metallic cation-naturally occuning polypeptide complex 
also preferably do not substantially cross-react with other 
metallic cations or other metallic cation-naturally occuning 
polypeptide complexes. A monoclonal antibody is substan-
tially non-crossreactive with other antigens if it does -not 
significantly react with the antigen over background levels 
in a standard ELISA reaction. Preferably, a non-crossreae-
tive antigen binds to the antibody with a disassociation 
constant of 10-4 or less. Monoclonal antibodies of the 
invention preferably have a disassociation constant of about 
10-4 to 10-13 , and preferably about 10-7 to 1O-!1. The 
monoclonal antibody specific for a metallic cation or a 
metallic cation-naturally oceuning polypeptide complex can 
be used to detect the amount of a metallic cation present in 
a sample of a body fluid or can be uscd as capture antibody 
to remove metallic cation containing naturally occuning 
polypeptides from the sample of body Ouid. The preferred 
monoclonal antibodies arc capable of dctecting metallic 
cations in a sample of body Ouid with as low as I Ilg/dl (10 
ppb) of metallic cation. 
Metallic cations include cations of the alkali earth metals, 
10 
for mercury. This monoclonal antibody has a disassociation 
constant of 2.3xlO-9M for HgCI2 . This monoclonal anti-
body does not substantially cross-react with barium chlo-
ride, cadmium chloride, chromic chloride, copper chloride, 
5 ferrous sulfate, gold chloride, nickel chloride, selenium 
oxide, silver chloride, and zinc chloride. Monoclonal anti-
bodies to lead have also been generated. The preferred 
monoclonal antibody is specific for Pb and does not cross-
react with other similarly structured metal ions. 
10 Monoclonal antibodies specific for lead and mercury 
cations have been deposited with the American Type Culture 
Collection (ATCC) on Mar. 13, 1990. Monoclonal antibody 
BN No. 4AI0B4, ATCC Accession No. HB 10381, has a 
dissociation constant for mercury cation of less than about 
10-9 but does not bind cadmium, copper, zinc, lead, nickel 
15 and cobalt cations to any appreciable extend. 
Antibodies of the invention can also bind to an epitope of 
a metal cation naturally occuning polypeptide complex such 
as Pb complexed with ALAD. Preferably, the antibody does 
not substantially crossreact with other metallic cation natu-
20 rally occuning polypeptide complexes such as Zn com-
plexed with ALAD. Optionally, the antibody may also be 
capable of binding to the uncomplexed metallic cation. This 
antibody is also substantially non-crossreactive with the 
naturally occuning polypeptide uncomplexed with the 
25 metallic cation such as ALAD without Pb. The naturally 
occuning polypeptide complexed with the metal cation can 
also be an enzyme so that the antibodies can recognize a 
metal cation enzyme complex. A preferred monoclonal 
antibody is a monoclonal antibody specific for lead com-
30 plexed with ALAD. An antibody with specificity for lead-
ALAD and designated 14F11 has been deposited with the 
American Type Culture Collection, Rockville, Md. on Apr. 
16, 1993 and given Accession No. HB 11330. 
A metallic cation-naturally occuning polypeptide com-
35 plex can be formed by incubating a naturally occuning 
polypeptide that binds the metallic cation with the metallic 
cation or can be formed by exposure of the animal to the 
metallic cation in vivo. A naturally occuning polypeptide 
that is known to bind metallic cations can be isolated and 
40 purified from an animal or a naturally occuning polypeptide 
that binds metallic cations can be identified by a method of 
the invention. A naturally occuning polypeptide can have a 
native metallic cation cofactor and can bind to a different 
metallic cation which then displaces the native metallic 
45 cation cofactor. A naturally occurring polypeptide binds to 
the metallic cation with sufficient strength to withstand 
several washings of the complex. Preferably, a naturally 
occuning polypeptide binds to or coordinates with the 
metallic cation with a disassociation constant of 10-4 to 
50 10-13. 
the transition metals, i.e., those clements in the periodic 
table with their outermost electrons in the dn orbitals, Group 
IIIa metal/metalloids (B, AI, Ga, In, and TJ), Group IVa 
metal/metalloids (Si, Ge, S, and Pb), and Group Va metal/55 
metalloids (As, Sb and Bi). The metallic cation can be 
monovalent or multivalent, but arc preferably divalent and 
can be bound to another organic moiety, e.g. methylmercury. 
More preferably, the metallic cation is a toxic metallic cation 
known to be harmful to humans and other animals, as 60 
described in Handbook on the Toxicology of Metals, cited 
supra. Typically, toxic metallic cations are those that bind to 
sulfhydryl containing polypeptides including lead, mercury, 
cadmium, copper, and methylmercury. The preferred metal-
Suitable examples of naturally occuning polypeptides 
that bind to metallic cations include o-aminolevulinic dehy-
dratase (ALAD), hemoglobin, heme synthetase, copropor-
phyrinigen decarboxylase, ALA synthetase, human serum 
albumin, glutathione, pyrimidine 5' nucleotidase, protein 
kinase C, and metallothioneins. The preferred metallic cat-
ion-naturally occuning polypeptide complex is lead-ALAD. 
The strategy for forming monoclonal antibodies immu-
noreactive with bare or uncomplexed metallic cations is that 
described in copending application U.S. Ser. No. 324,392 
filed on Mar. 14, 1989. The monoclonal antibodies to 
metallic cations are formed in response to an immunogen 
having characteristics that allow for the metallic cation to 
remain in a'substantially exposed state so that it is available 
lic cations are lead, mercury, cadmium, and gallium. 
Suitable examples of monoclonal antibodies specific for 
metallic cations include monoclonal antibody 4AlO specific 
65 to react with the cells of the immune system. 
The immunogen compounds for generation of the specific 
immunogenicity of the monoclonal antibodies for metallic 
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cations are based upon the hapten-carrier concept. In the 
present invention, hapten is coordinated at the end of a 
spacer arm covalently bonded to a carrier. The spacer arm is 
adapted so as to be semi-rigid and to hold the metallic cation 
in an exposed position relative to the carrier. This arrange-
ment is also adapted to maintain the metallic cation in a 
substantially exposed state. These factors combine substan-
tially to avoid chelating, uncovering or inclusion of the 
metallic cation by the spacer and/or the carrier. 
The spacer arm, as characterized above, may be an 
oligopeptide, an aliphatic compound, or an aliphatic frag-
ment. In the later two instances, the aliphatic compound or 
fragment may be covalently bonded to the carrier by means 
of a Schiff base reaction with an aldehyde group; an amide 
reaction with an amine or carboxylic acid group using a 
peptide activator such as carbodiimide, acid chloride and the 
like; and an ester reaction with a hydroxyl or carboxylic acid 
group using a Shotten-Bauman reaction or azide or acid 
catalysis reaction; a sulfide reaction using sulfide coupling 
agent or other known coupling reactions for joining organic 
molecules to proteins. See, for example, E. A. Kabat, 
Structural Concepts in Immunology and Immunochemistry, 
2nd edition, Holt, Rheiner & Winston, New York (1976) (a 
review text of such methods); and Jaime Eyzaguirre, Chemi-
cal Modification of Enzymes: Active Site Studies, Chichester, 
Westsussex, England, Halsted Press (1987). The oligopep-
tide, aliphatic compound or fragment will contain backbone 
groups which provide semi-rigidity to the spacer arm. Pre-
ferred groups for developing this semi-rigidity include pep-
tide bonds, olefin bonds, olefinic conjugated systems, ester 
groups and enone groups. Optionally, one or more aromatic 
rings can be incorporated into the spacer arm to stimulate the 
development of an immune response. 
In general, the oligopeptide spacer arm has the following 
formula: 
-X-(R)-Y 
wherein X is a coupling group that will bond to the carrier, 
R is one or more amino acid residues, and Y is the Lewis 
acid or base group for metallic cation coordination. 
In general, the aliphatic compound or fragment spacer 
arm has the following formula: 
-X-(Q)-Z 
wherein X is a coupling group that will bond to the carrier, 
Q is a semi-rigid aliphatic moiety containing ester amide 
keto, olefin or aromatic groups and the like, and Z is the 
Lewis acid or base group for metallic cation coordination. 
12 
(KLH). Once formed, the carrier spacer arm is incubated 
with the metallic cation to form an immunogen. The immu-
nogen is administered to an animal parenterally, most often, 
either subcutaneously or intraperitoneally with an adjuvant. 
5 Administration of the immunogen is repeated at least four 
times. After repeated immunization, polyclonal sera can be 
harvested. 
Monoclonal antibodies are formed by standard methods, 
as described previously. Briefly, spleens from the immu-
10 nized animals are harvested and spleen cells separated. 
Spleen cells are fused with myeloma cells to form hybri-
doma cells. Hybridoma ceIls are selected and incubated in 
vitro. The presence of monoclonal antibodies specific for 
metallic cations in the hybridoma cell culture medium is 
15 assayed by ELISA. Hybridoma secreting monoclonal anti-
bodies are selected for specificity to metallic cations. 
The monoclonal antibodies can be selected by one or 
more selection techniques. One selection technique selects 
for the ability of the monoclonal antibodies to immunoreact 
20 with the metallic cation and to not substantially cross-react 
with the carrier spacer arm conjugate. The monoclonal 
antibodies can also be selected to not substantially cross-
react with other metallic cations. A monoclonal antibody is 
not substantially crossreactive with an antigen if it doesnot 
25 react with that antigen significantly above background level 
in a standard ELISA assay. Preferably, the monoclonal 
antibody binds to a non-crossreactive antigen with a disas-
sociation constant of 10-4 or less. The monoclonal antibod-
ies can also be selected to bind to the metallic cation portion 
30 of a metallic cation-naturally occurring polypeptide com-
plex. The preferred monoclonal antibody is specific for a 
metallic cation, does not substantially cross-react with the 
carrier spacer arm or other metallic cations, and binds to the 
metallic cation portion of a metallic cation-naturally occur-
35 ring polypeptide complex. 
A preferred application contemplates the production of 
monoclonal antibodies specific for the mercuric cation or 
another toxic heavy metal cation. The heavy metal cation is 
combined into an immunogen compound, as described 
40 above, and suspended in aqueous medium. The preferred 
protein carrier for the immunogen compound in this instance 
is keyhole limpet hemocyanin. The preferred spacer arm in 
this instance is an oligopeptide which has sulfhydryl groups 
capable of coordinating with the heavy metal cation. Glu-
45 tathione is especially preferred as the spacer arm. The 
suspension of the immunogen compound is used to immu-
nize a host mammal, such as a mouse, following the tech-
niques outlined above. The laboratory strain of mouse 
designated BALB/c is particularly preferred. 
Antibody producing cells of the immunized host spleen 
are collected and converted into a suspension. These spleen 
ceIls are fused with immortal cells. Preferably myeloma 
cells of the same animal species as the immunized host are 
used as a fusion partner. Typically, a cell fusion promoter, 
Preferably, an oligopeptide or aliphatic compound is used 50 
as the spacer arm for a metallic cation. In this instance, the 
pendant Lewis base groups will preferably be positioned at 
the spacer arm and remote from the carrier. These Lewis 
base groups function as a coordination site or sites for the 
metallic cation. It is preferable that the deformity of the 
electron shells of the Lewis base groups and the metallic 
cations be approximately similar. Accordingly, sulfur groups 
can serve as the Lewis base groups when the metal cations 
55 such as polyethylene glycol, is employed to cause formation 
of the hybridoma cells. The hybridoma cells are diluted and 
cultured in a medium which does not allow for the growth 
of unfused cells. 
are transition metals or inert transition elements. Nitrogen-
containing groups are preferably employed as Lewis base 
groups when aluminum, lithium, boron, strontium, and 
magnesium are the metallic cations. 
Carrier molecules are typically large molecular weight 
proteins that can function to concentrate the carrier spacer 
arm metallic cation complex. Suitable carrier molecules 
include proteins that are not enzymatically active such as 
bovine serum albumin (BSA) or keyhole limpet hemocyanin 
The monoclonal antibodies produced and secreted by the 
60 hybridomas are thereafter assayed for the ability to bind 
specifically with the heavy metal cations used for immuni-
zation. They are further selected for lack of cross-reactivity 
with the carrier and with carrier spacer arm. The preferred 
assay method in this context is an enzyme-linked immun-
65 osorbent assay. 
The resulting monoclonal antibodies are specific for toxic 
heavy metal cations and exhibit strong disassociation con-
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teins and polypeptides present in the sample. The antibody 
will preferably bind the naturally occurring polypeptide 
whether or not it is complexed with one or more metallic 
cations. A polyclonal antiserum to red cell proteins or serum 
stants for the heavy metal cations when in the presence of 
spacer arm, the spacer arm carrier composition, and other 
similarly structured cations. Preferred monoclonal antibod-
ies are selectively immunoreactive with cations of mercury, 
lead, cadmium, strontium, nickel, cobalt, gold, or arsenic. 
Polyclonal and monoclonal antibodies specific for a 
metallic cation-naturally occurring polypeptide complex can 
be formed by immunizing an animal with the naturally 
occurring polypeptide complexed with the metallic cation, 
5 proteins can be used to effectively capture substantially all 
polypeptides that bind the metallic cation and provides for a 
sensitive detection of the metallic cation contamination of 
the body fluid. Preferably, the antibody is a monoclonal 
as described previously. The antibodies formed and selected 10 
can be specific for the metallic cation portion of the metallic 
cation-naturally occurring polypeptide complex or a peptide 
epitope on the naturally occurring polypeptide portion of the 
metallic cation-naturally occurring polypeptide complex. A 
monoclonal antibody specific for an epitope on the naturally 15 
occurring polypeptide portion of the complex does not 
substantially cross-react with epitopes on the naturally 
occurring polypeptide not complexed with the metallic 
cation. The preferred monoclonal antibodies are selected for 
specificity for an epitope found on the metallic cation- 20 
naturally occurring polypeptide complex and not found on 
the naturally occurring polypeptide complexed with a dif-
ferent metallic cation. The monoclonal antibodies can also 
be further selected to not substantially cross-react with other 
metallic cation-naturally occurring polypeptide complexes. 25 
The especially preferred monoclonal antibody is a mono-
clonal antibody that is specific for lead-ALAD complex and 
does not substantially cross-react with ALAD. 
C. Method for Detecting a Metallic Cation in a Body Fluid 
The invention provides a preferred method for detecting 30 
a metallic cation in a sample of a body fluid utilizing two 
different antibodies. The method involves contacting an 
effective amount of a capture antibody of the first type with 
the sample of body fluid suspected of containing the metallic 
cation to form a first antigen-antibody complex. This step 35 
functions to capture a naturally occurring polypeptide that 
binds the metallic cation from the body fluid. Then, an 
effective amount of the second type of antibody is added to 
the first antigen-antibody complex to form a second antigen-
antibody complex. This antibody can be any of the three 40 
specific SUbtypes mentioned above. The antibody can also be 
specific for an epitope formed in response to a metallic 
cation bound to a spacer arm-carrier conjugate immunogen. 
The second antigen-antibody complex includes the first type 
of antibody, the naturally occurring polypeptide, the metallic 45 
cation and the second type of antibody. The amount of the 
metallic cation in the sample of body fluid is determined by 
detecting the amount of the second antigen-antibody com-
plex. The amount of the second antigen-antibody complex is 
preferably proportional to the amount of the metallic cation 50 
in the sample. 
A sample of the body fluid suspected of containing a 
metallic cation is obtained from an animal species. All 
animal species can contain metallic cations, especially toxic 
metallic cations. Suitable body fluids include any fluid that 55 
might contain a naturally occurring polypeptide that binds 
the metallic cation. The preferred body fluids are those that 
are easily obtained from the animal, including blood, urine, 
saliva, and cerebral spinal fluid. Preferably the sample of 
body fluid is treated with a lysing agent to lyse cells present 60 
in the body fluid. Cells in the sample of body fluid can also 
contain a naturally occurring polypeptide that bind the 
metallic cation. Suitable lysing agents include surfactants 
such as Tween 80, Nonidet p40, Triton X-lOG, and the like. 
The first type of antibody selectively binds to the naturally 65 
occurring polypeptide in the sample of the body fluid to 
isolate the naturally occurring polypeptide from other pro-
antibody and, more preferably, is a monoclonal antibody 
specific for an epitope shared by the naturally occurring 
polypeptide from many animal species. The especially pre-
ferred monoclonal antibody is specific for ALAD. An effec-
tive amount of the antibody is that amount of antibody that 
is sufficient to bind substantially all of the naturally occur-
ring.polypeptide from the sample of body fluid. An effective 
amount of the antibody can be determined by measuring the 
total protein level in the sample of body fluid by standard 
methods. 
The second type of antibody is added to the first antigen-
antibody complex and allows the determination of the 
amount of the metallic cation present in the sample. The 
antibody can be specific for the metallic cation portion or for 
the naturally occurring polypeptide portion or for the com-
bination of the metallic cation and coordinate polypeptide 
portion of the metallic cation-naturally occurring polypep-
tide complex. The antibody can also be specific for a 
metallic cation not complexed with a naturally occurring 
polypeptide. When the antibody is specific for the naturally 
occurring polypeptide portion or the combination of the 
metallic cation-naturally occurring polypeptide complex, it 
does not substantially cross-react with the naturally occur-
ring polypeptide not complexed with the metallic cation 
(Le., alone). The preferred antibody is a monoclonal anti-
body for a metallic cation. The especially preferred antibody 
is a monoclonal antibody for a toxic metallic cation, such as 
lead, cadium, mercury, and gallium. An effective amount of 
the antibody specific for an epitope on a metallic cation-
naturally occurring polypeptide complex is that amount that 
is sufficient to bind substantially all of the first antigen-
antibody complex. 
The preferred method of the invention can also be con-
ducted in reverse order. A sample of the body fluid contain-
ing the metallic cation bound to a naturally occurring 
polypeptide can first be contacted with a capture antibody 
that is of the second type to form a first antigen-antibody 
complex. For example, monoclonal antibodies specific for 
lead can be used to bind lead and lead complexed with the 
naturally occurring polypeptides in the sample of the body 
fluid. An antibody of the first type can then be added to form 
the second antigen-antibody complex. The amount of the 
metallic cation in the sample of body fluid is determined by 
detecting the amount of second antigen-antibody complex. 
The amount of the second antigen-antibody complex is 
preferably proportional to the amount of metallic cation 
present in the sample of body fluid. 
The preferred method of the invention can also be prac-
ticed through use of the second type of antibody as both the 
capture and detection antibody. If multiple epitopes of the 
same structure appear on the metallic cation-naturally occur-
ring polypeptide complex, the same subtype of second 
antibody can be used twice. If not, then differing subtypes 
will be used. Capture and detection procedures are con-
ducted as described for the foregoing versions of the method 
of the invention. 
The antibody used first to contact the sample of the body 
fluid is preferably immobilized onto a solid substrate. The 
antibody can be immobilized onto a solid substrate by a 
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variety of methods, as described in Antibodies: A Labora-
tory Manual, cited supra. 
Suitable solid substrates include materials having a mem-
brane or coating supported by or attached to sticks, synthetic 
glass, agarose beads, cups, flat packs, or other solid supports. 
Other solid substrates include cell culture plates, ELISA 
plates, tubes, and polymeric membranes. The preferred solid 
substrate is a stick coated with a polymeric membrane. 
An antibody that is added to the first antigen-antibody 
complex to form a second antigen-antibody complex is 
preferably labelled with a detectable agent so that the second 
antigen-antibody complex can be easily detected. The anti-
body can be labelled with a detectable agent by standard 
methods, as described in Antibodies: A Laboratory Manual, 
at pages 319-358, cited supra. The method for labelling the 
antibody with a detectable agent depends on the type of 
detectable agent and is conducted so that the labelling of the 
antibody does not interfere with the capability of the anti-
body to bind to the antigen. 
Suitable detectable agents include enzymes, radioactive 
labels, fluorochromes, and biotin. The preferred detectable 
agents are enzymes, such as horseradish peroxidase, alkaline 
phosphatase, and ~-galactosidase. 
The means for detecting the second antigen-antibody 
complex depend on the detectable agent coupled to the 
antibody. If the detectable agent is a radioactive label, like 
1125 or S35, then the second antigen-antibody complex is 
detected by measuring radioactive decay in a scintillation 
counter. If the detectable agent is a fluorochrome, the second 
antigen-antibody complex is detected by measuring fluores-
cent energy emissions spectrophotometrically. If the detect-
able agent is an enzyme, the second antigen-antibody com-
plex is detected by enzymatic conversion of a substrate. 
In a preferred version, the detectable agent is an enzyme 
and the means for detecting the detectable agent is a sub-
strate for that enzyme. The substrate is preferably a com-
pound that changes color as a result of the enzymatic 
activity. A sufficient amount of the substrate is added to 
ensure that the amount of substrate converted is proportional 
to the amount of the second antigen-antibody complex 
present in the sample. 
The metallic cation present in the sample of body fluid can 
be detected by determining the amount of the second anti-
gen-antibody complex and comparing it to a standard curve 
that correlates the amount of the second antigen-antibody 
complex with a known concentration of the metallic cation. 
The immunoassay, as described above, can be run with 
standard amounts of the naturally occurring polypeptide 
purified and mixed with different concentrations of the 
metallic cation ranging from about less than 0.5 Ilg/dl to 50 
Ilg/dl. For example, standard solutions containing the same 
amount of purified ALAD can be mixed with different 
concentrations of lead cations ranging from about 0.5 Ilg/dl 
16 
obtained and treated with Triton X-lOO to lyse the red blood 
cells. The sample is then contacted with an antibody specific 
for ALAD immobilized on an ELISA plate to form a first 
antigen-antibody complex. The plate is then washed to 
5 remove uncomplexed proteins, and an antibody specific for 
lead and labelled with horseradish peroxidase is added to the 
first antigen-antibody complex. After incubation and wash-
ing, the substrate for horseradish peroxidase, ABTS is 
added. Conversion of the substrate to the product is mea-
10 sured spectrophotometrically at 405 nanometers. The 
amount of lead cation in the blood sample is determined by 
reference to the standard curve. 
This method can be used to detect a plurality of different 
metallic cation-naturally occurring polypeptide complexes 
15 in a body fluid. For example, immunoassays can be run 
concurrently using several different antibodies specific for 
different naturally occurring polypeptides that bind to metal-
lic cations. For example, the immunoassay can be run with 
either an antibody specific for ALAD, glutathione, and/or 
20 metallothionein. The amount of the metallic cation, such as 
lead, complexed with each of these polypeptides in the blood 
sample can be compared and can be used to determine the 
amount and duration of the metallic cation exposure. 
A method of the invention can also provide for a deter-
25 mination of whether an animal has been exposed acutely or 
chronically to the metallic cation. While not in any way 
meant to limit the invention, it is believed that some natu-
rally occurring polypeptides, such as ALAD, bind to the 
metallic cation within a short time of exposure (e.g. 3 hours 
30 or less) and other naturally occurring proteins do not bind 
the metallic cation until there has been a prolonged exposure 
(e.g. at least 24 hours). A comparison of the amount of the 
metallic cations bound by these two different types of 
polypeptides can indicate whether the exposure is acute or 
35 chronic. A comparison of metallic cation binding by the 
acute binding protein and two or more of the chronic binding 
protein can indicate whether there has been recent acute 
exposure as well as chronic exposure. For example, if 
substantiall y all of the metallic cation is detected bound to 
40 a polypeptide that binds the metallic cation within a short 
time of exposure, such as ALAD, it is likely that the animal 
was acutely exposed. Binding of substantially all of the 
metallic cation means preferably binding of about 80-100% 
of the total metallic cation detected binding to both types 
45 polypeptides and more preferably about 90-100%. 
If the metallic cation is detected bound to several natu-
rally occurring polypeptides, including those polypeptides 
that bind the metallic cation after a short and a long 
exposure, then it is likely the animal has been chronically 
50 exposed to the metallic cation. For a chronic exposure, 
preferably binding to the first type of naturally occurring 
polypeptide is about 10-60%, and binding to the second type 
of naturally occurring polypeptide is about 20-70% of the up to 50 Ilg/dl. These standard solutions are then contacted 
with an antibody specific for ALAD to form a first antigen-
antibody complex. An antibody specific for the lead labelled 55 
with horseradish peroxidase is then added to the first anti-
gen-antibody complex to form the second antigen-antibody 
complex. The amount of the second antigen-antibody com-
plex is measured by conversion of the substrate for horse-
radish peroxidase, 2,2'-azino-di-[3-ethyl-benzothiazoline 
sulfonate(6)] (ABTS). ABTS is converted to a colored 
product which is measured spectrophotometrically at 405 
nanometers. A standard curve is constructed by plotting the 
amount of lead cation added to the original sample against 
the amount of substrate converted. 
total metallic cation bound to both polypeptides. 
The steps of the method include detecting the amount of 
the metallic cation bound to a first type of naturally occur-
ring polypeptide, detecting the amount of the metallic cation 
bound to one or more second type of naturally occurring 
polypeptides and comparing the amount of metallic cation 
60 bound by the first type of polypeptide to the other polypep-
tides. Preferably the first type of polypeptide is a naturally 
occurring polypeptide that binds the metallic cation within a 
short period of time after exposure, preferably within about 
3-24 hours. The preferred polypeptide that binds the metal-
65 lie cation after a short period of exposure is ALAD. The 
second type of polypeptide is preferably a polypeptide that 
binds the metallic cation after a longer duration, preferably 
In a preferred version, the method detects the amount of 
lead cations present in human blood. A blood sample is 
5,532,136 
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after at least about 24 hours, and more preferably about 
24-72 hours. The preferred polypeptide that binds the metal-
lic cation after a longer exposure is hemoglobin. 
The amount of metallic cation bound by a naturally 
occurring polypeptide upon an acute exposure (i.e., the first 5 
type) can be compared to the amount of metallic cation 
bound by one or more naturally occurring polypeptides that 
bind to metallic cations after a chronic exposure (Le., second 
type). In a preferred version, the amount of metallic cation 
bound to a first type of polypeptide, such as ALAD, is 10 
compared to the amount of metallic cation bound to a second 
type of polypeptide, such as hemoglobin. 
The amount of metallic cation bound to the polypeptides 
can be detected by the immunoassay method of the inven-
tion. For example, the amount of a metallic cation such as 15 
lead bound to a first type of naturally occurring polypeptide 
can be determined by an immunoassay employing an anti-
body specific for ALAD as capture antibody and an antibody 
specific for lead cation to detect the amount of ALAD lead 
complex. The amount of lead bound to ALAD can be 20 
detected by comparison to a standard curve prepared using 
known standard as described previously. The amount of 
metallic cation such as lead bound to one or more other 
naturally occurring polypeptides, such as hemoglobin, can 
be determined in a similar manner except that the capture 25 
antibody in this case is an anti-hemoglobin antibody. The 
amount of the metallic cation bound preferably is measured 
as a percentage of the total amount of metallic cation 
detected binding to each of the polypeptides. 
The immunoassay method of the invention can be option- 30 
ally performed in a number of different variations depending 
on the specificity of the antibody employed. Some of these 
alternate embodiments are described below. 
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lead-ALAD in the presence of a chelator such as ethylene 
diaminetetraacetic acid followed by an excess of Zn+2 ions. 
After removal of the lead cations, the restored enzyme 
activity can again be measured. The amount of restored 
enzyme activity can be used to determine the amount oflead 
cation bound to ALAD. 
In another alternate version, a method of the invention can 
employ a single antibody specific for a naturally occurring 
polypeptide that binds at least two metallic cations per 
polypeptide. An antibody specific for a naturally occurring 
polypeptide that binds at least two metallic cations is first 
used as a capture antibody to immobilize the naturally 
occurring polypeptide from the sample of body fluid. The 
same antibody can then be employed to detect the amount of 
the naturally occurring polypeptide that binds at least two of 
the metallic cations immobilized. Preferably, the antibody is 
specific for (1) the metallic cation or (2) the metallic cation 
portion of, or (3) the combination of metallic cation and 
coordinate polypeptide portion of the metallic cation-natu-
rally occurring polypeptide complex. For example, an anti-
body specific for lead cations can be used to capture a 
naturally occurring protein that binds at least two lead 
cations per polypeptide, such as ALAD. While not in any 
way meant to limit the invention, it is believed that the other 
lead cation bound to the polypeptide can then be detected. 
Once the naturally occurring polypeptide that binds at least 
two of the metallic cations per polypeptide is captured or 
immobilized, the amount of bound lead cation can be 
detected using the same antibody specific for lead cations 
but labelled with a detectable agent, as described previously. 
These alternate embodiments ofthe immunoassay method 
of the invention can also provide for a rapid, low cost 
detection of metallic cation contamination in a sample of 
body fluid. 
D. Immunoassay Kit for Determining the Amount of a 
Metallic Cation in a Sample of Body Fluid 
The invention also provides kits for detecting one or more 
metallic cations in a sample of body fluid. The preferred kit 
contains at least two antibodies having different specificities. 
One of the antibodies can be a first type antibody while the 
other antibody can be a second type antibody. Alternatively 
both antibodies can be of the second type as described 
above. One of the antibodies in the kit is preferably immo-
bilized on a substrate and the other type of antibody is 
preferably labelled with a detectable agent. The antibody 
immobilized on the substrate is preferably not labelled with 
the detectable agent. The antibody not immobilized on the 
substrate is preferably labelled with a detectable agent. 
The antibodies are present in the kit in an amount effective 
to bind to and detect substantially all of the naturally 
occurring polypeptide that binds the metallic cation in the 
sample of body fluid. 
The preferred antibody specific for a naturally occurring 
polypeptide that can bind metallic cation is capable of 
binding substantially all of the naturally occurring polypep-
Not all embodiments of the method of the invention 
require two antibodies having different specificities. For 35 
example, a method of the invention includes using a single 
antibody specific for a naturally occurring polypeptide or 
metallic cation-naturally occurring polypeptide complex to 
serve as a capture antibody. The capture antibody binds the 
naturally occurring proteins that bind the metallic cation 40 
from the sample of body fluid. The naturally occurring 
polypeptide in this case is an enzyme whose activity is 
inhibited by the binding of the metallic cation. Once the 
naturally occurring polypeptide that binds the metallic cat-
ion is immobilized by the capture antibody, enzyme activity 45 
is measured. Enzyme activity can be restored by removal of 
the metallic cation that inhibits the enzyme activity. 
Removal of the metallic cation can be accomplished by 
using a chelating agent to bind thc metallic cation or by 
adding an excess of the native cofactor or using a combi- 50 
nation of both treatments. After removal of the metallic 
cation that inhibits enzyme activity, the restored enzyme 
activity is measured. The amount of the restored enzyme 
activity is an indicator of the amount of the inhibiting 
metallic cation bound to the enzyme. 55 tide from the sample of body fluid in about 10 minutes or 
less. The especially preferred antibody specific for a natu-
rally occurring polypeptide that binds the metallic cation is 
an antibody specific for ALAD. 
Typically, enzymes that bind to metallic cations and 
assays for their activity are known to those of skill in the art. 
For example, ALAD is an enzyme that binds to lead cations 
and whose activity is inhibited by the binding oflead cations 
in place of the native cofactor Zn+2 . Tsukamoto et al., 60 
Biochern. Biophys. ACTA, 570:167 (1979). An antibody 
specific for ALAD or lead-ALAD can be used to capture the 
ALAD-Pb complexes from the body fluid. The enzyme 
activity of ALAD in the Pb-ALAD complexes can be 
determined by standard methods as described in Mauzerall 65 
and Granick, J. BioI. Chern., 219:435 (1956). Removal of 
the lead cation can be accomplished by incubating the 
The preferred antibody specific for an epitope (polypep-
tide portion or combination) on metallic cation-naturally 
occurring polypeptide complex or a metallic cation is 
capable of detecting concentration of the metallic cation in 
a sample of fluid containing at least about 1 Ilg/dl metallic 
cation. The especially preferred antibody is an antibody 
specific for lead cations. 
The kit can contain any number of combinations of the 
different types and subtypes of antibodies. For example, the 
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product. The especially preferred combination of detectable 
agent and means for detecting the detectable agent is horse-
radish peroxidase and 2,2'-azino-di-[3-ethyl-benzothiazo-
line sulfonate] (ABTS). 
The kit also optionally contains a lysing agent that func-
tions to lyse cells present in the sample of body fluid. 
Suitable lysing agents include surfactants such as Tween-80, 
Nonidet P40, and Triton X-IOO. Preferably, the lysing agent 
is immobilized onto the solid substrate along with one of the 
kit can contain an antibody specific for a metallic cation and 
several different antibodies specific for different naturally 
occurring polypeptides that can bind the metallic cation. 
Altematively, the kit can contain several different antibodies 
specific for different metallic cations and one antibody 5 
specific for a naturally occurring polypeptide that can bind 
the metallic cations. Alternatively, the kit can contain a 
plurality of antibodies specific for metallic cations and a 
plurality of antibodies specific for naturally occurring 
polypeptides that can bind the metallic cations. The kit can 
also containing a third type of anti-immunoglobulin anti-
body that is anti-IgG, anti-IgM, or anti-IgA, preferably 
labelled with a detectable agent. The preferred kit contains 
one monoclonal antibody specific for a naturally occurring 
polypeptide that binds the metallic cation and one mono-
10 antibodies. 
clonal antibody specific for a metallic cation. 15 
The kit can also contain a buffer solution for washing of 
the substrate between steps. The buffer solution is a physi-
ological solution such as a phosphate buffer, physiological 
saline, citrate buffer, or Tris buffer. 
The kit can also include standards containing different 
Alternatively, the kit can contain a single type of antibody. 
For example, the kit can contain an antibody specific for a 
metallic cation that can be used to detect the amount of lead 
cation bound by a naturally occurring polypeptide that binds 
at least two of the metallic cations per polypeptide, as 
described previously. 
Optionally, the kit can contain a capture antibody specific 
for an enzyme that is inhibited by the metallic cation, and 
components for measuring the enzyme activity, as described 
previously. For example, the kit could provide an antibody 
to ALAD, reagents for restoring the enzyme activity such as 
EDTA and/or solution containing Zn+2 ions and the reagents 
required to measure ALAD enzyme activity such as 
O-amino-levulinic acid. 
One of the types of antibodies is preferably immobilized 
on a solid substrate. Antibodies can be immobilized onto 
solid substrates by standard methods, as described in Anti-
bodies: A Laboratory Manual, cited supra. Suitable solid 
substrates include materials having a membrane or coating 
supported by or attached to sticks, cups, flat packs, or other 
solid supports. Other solid substrates include cell culture 
plates, ELISA plates, tubes, and polymeric membranes. The 
preferred solid substrate is a stick coated with a polymeric 
membrane. 
One of the types of antibodies is preferably labelled with 
a detectable agent, typically the antibody not immobilized 
on the substrate. Antibodies can be labelled with detectable 
agents by standard methods, as described in Antibodies: A 
Laboratory Manual, at pages 319-358, cited supra. Suitable 
detectable agents include enzymes, radioactive labels, fluo-
rochromes, and biotin. The preferred detectable agent for 
use in the kit is an enzyme, and more preferably, an enzyme 
that converts a substrate into a color product that can be 
detected visually. 
The kit optionally contains means for detecting the detect-
able agent. Ifthe antibody is labelled with a radioactive label 
or a fluorochrome, preferably no means for detecting the 
agent is provided in the kit. Typically, the consumer will 
have spectrophotometers, scintillation counters, and micro-
scopes that can be used to detect these detectable agents. If 
the detectable agent is biotin or an enzyme, means for 
detecting the detectable agent can be supplied with the kit. 
Suitable examples of means for detecting the detectable 
agent include a substrate for the enzyme or avidin. The 
means for detecting the detectable agent is present in a 
sufficient concentration to detect substantially all of the 
second antigen-antibody complex. Preferably, the substrate 
for the enzyme is provided in a ratio of about 2: I to 100: 1 
with the amount of antibody labelled with enzyme present in 
the kit. 
The preferred means for detecting the detectable agent is 
a substrate that is converted by the enzyme into a colored 
concentrations of a metallic cation-naturally occurring 
polypeptide complex. The standards can be prepared by 
mixing different amounts of the metallic cation ranging from 
0.5 Ilgfdl to 50 Ilgldl with a single concentration of a 
20 naturally occurring polypeptide that binds metallic cations. 
Solutions containing different amounts of a metallic cation-
naturally occurring polypeptide complex are then formed 
and run in the immunoassay methods of the invention. 
In a preferred version, each of the standard solutions is 
25 contacted with a first type of antibody to form a first 
antigen-antibody complex. A second type of antibody 
labelled with a detectable agent is then added to form the 
second antigen-antibody complex. The amount of second 
antigen-antibody complex is detected by measuring the 
30 amount of detectable agent. The amount of the second 
antigen-antibody complex is measured for each of the stan-
dard solutions and then plotted against the concentration of 
the metallic cation initially added to each of the standard 
solutions. In addition, the amount of the metallic cation 
35 present in the second antigen-antibody complex can be 
measured by atomic absorption spectroscopy and the abso-
lute amount of the metallic cation bound to the naturally 
occurring polypeptide can be compared to the amount of 
metallic cation initially added and to the amount of the 
40 second antigen-antibody complex determined by detecting 
the detectable agent. 
Optionally, one or more of the standards containing the 
different concentrations of the metallic cation-naturally 
occurring polypeptide complex can be immobilized onto a 
45 portion of the solid substrate. Preferably, three different 
standards can be immobilized, each in a different portion of 
the solid substrate. For example, standards containing a 
naturally occurring polypeptide mixed with 1,5 and 10 Ilg/dl 
can be immobilized onto the solid substrate by binding to the 
50 immobilized antibody specific for the naturally occurring 
polypeptide. A portion of the immobilized solid substrate is 
available for binding of the test sample of the body fluid. 
When the immunoassay is completed by conversion of the 
enzymatic substrate to a colored product, the amount of 
55 colored product produced by the test sample of body fluid 
can then be immediately compared with the amount of 
colored product produced for each of the standard amounts. 
Optionally, the kit can include a card with a visual 
representation of the amount of colored product produced by 
60 a particular amount of a standard containing a naturally 
occurring polypeptide mixed with a known concentration of 
the metallic cation. Preferably, the card contains a plurality 
of different visual representations of the different intensities 
of colored product associated with the different amounts of 
65 the standard concentrations of the metallic cation. This card 
can be used by the consumer to compare the amount of the 
colored product produced with the test sample of a body 
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fluid and, thereby, quantitate the amount of metallic cation 
present in the sample of body fluid. 
In a preferred kit, an antibody specific for ALAD is 
immobilized onto a portion of a dipstick composed of 
membrane attached to a stick. The antibody specific for 5 
ALAD is capable of binding substantially all of the ALAD 
present in the sample in less than about 10 minutes. The 
dipstick also has a lysing agent immobilized along with the 
antibody specific for ALAD, preferably Triton X-100. The 
preferred kit also contains a phosphate buffer solution and an 10 
antibody specific for the lead cation labelled with horserad-
ish peroxidase. The antibody specific for lead cation is 
preferably an antibody that can detect lead cation in samples 
of body fluids containing as low as about 1 Ilg/dl of lead 
cation. The preferred kit also contains a substrate for horse- 15 
radish peroxidase, preferably ABTS. The preferred kit also 
contains a card with a plurality of visual representations of 
different amounts of colored product formed by conversion 
22 
TABLE I-continued 
Reactivity of Serum from 
BALB/c Mice Injected with BSA-glutathione-HgCl 
Mouse # BSA-GSH BSA-GSH-HgCl % Difference 
8 1.670 1.456 -12.8 
background 0.299 0.308 
One hundred microliters of serum was added to the 
wells of microtiter plates to which either BSA-glutathione 
or BSA-glutathione-HgCl had been adsorbed. After 
incubation for 2 hours at room temperature, the plate was 
washed three times with PBS followed by addition of 100 ;U 
of goat anti-mouse serum. The plate was incubated and 
washed as above, then 100 ;U of rabbit anti-goat serum 
conjugated with alkaline phosphatase was added. After 
incubation and washing as above, 100 ;U of 2 mM para-
nitrophenyl phosphate in 1M diethanolarnine, pH-9.6, 
containing 25 mM MgC12 , was added, and the A405 of each well 
was measured after incubation at room temperature of 15-30 
minutes. Percent difference was calculated by the 
+3.0 
of ABTS by horseradish peroxidase for different standard 
amounts of samples containing the metallic cation. following formula: 20 Percent difference = I (A405 of BSA-GSH-Hg - A405 of 
BSA-GSH) + (A405 of BSA-GSH)] x 100. 
EXAMPLE I 
Preparation of Monoclonal Antibodies Binding to a 
Metallic Cation Mercury 25 
The strategy for both inducing and selecting metal cation-
specific antibodies was to prepare a complex in which the 
metal ion could be bound as a monodentate ligand. The 
coordination number of most metals, which denotes the 30 
number of ligands attached to the central metal atom in a 
complex, is generally four to six, although numbers from 
three to ten have been noted. (D. Craig et al., Chelating 
Agents and Metal Chelates, F. Dwyer and D. Mullon editors, 
pp. 51-93, Academic Press, NY (1966).) In the complex 35 
used in these experiments, mercuric chloride was added to 
glutathione (GSH), which is a tripeptide of L-y-glutamyl-
cysteinylglycine. The disassociation constant of mercuric 
ions bound to sulfhydryl groups has been reported to be as 
high as 1O-42M. Thus, the interaction is sufficiently strong 40 
that a stable complex can be formed by interaction of 
mercury with only the sulfhydryl group of cysteine, without 
requiring the participation of either the amino or carboxyl 
groups of the other two amino acids. (B. Fuhr et al., 1. Am. 
Chern. Soc., 95:6944 (1973).) 45 
The immunogen consisted of GSH-HgCl conjugated to a 
carrier protein keyhole limpet hemocyanin. BALB/c mice 
were given mUltiple intraperitoneal injections of the HgCI-
GSH-keyhole limpet hemocyanin emulsified in Freund's 
adjuvant, with a total of 50 Ilg of protein per injection. The 50 
mice were bled after the fifth injection, and their sera were 
analyzed by ELISA against bovine serum albumin (BSA)-
GSH and BSA-GSH-HgCl for evidence of mercury-specific 
antibodies. The results are shown in Table 1 below. 
Serum from an unimmunized mouse served as background 
reactivity for each antigen. 
The initial screening for the presence of mercury-specific 
antibodies in serum was simply higher reactivity with the 
immunogen containing mercury than with immunogen not 
containing mercury. Several mice, (e.g., #'s 2, 4,5,6, and 7) 
satisfied this condition. 
Mouse #6 was given a booster injection, and its spleen 
was used for fusion three days later. The ELISA procedure 
used to screen the hybridoma culture fluids was the same as 
described in the legend to Table 1. 
TABLE 2 
Reactivity of Hybridoma Antibodies with 
BSA-glutathione-HgCl and BSA-glutathione 
Hybridoma BSA-GSH-HgCI BSA-GSH 
IHll 1.246 1.202 
2A9 0.758 1.052 
3A12 1.792 2.217 
3H9 1.606 2.134 
IFIO 1.175 0.406 
3E8 1.076 0.410 
4AlO 1.104 0.400 
Neg. control 0.428 0.456 
Of 134 hybridomas obtained, seven of them demonstrated 
reactivity consistent with specificity for some part of the 
GSH-HgCI component of the immunogen (Table 2). MAb's 
1Hll, 2A9, 3A12, and 3H9 showed a pattern consistent with 
GSH-specificity, since they reacted with GSH whether 
HgCI2 was present or not. On the other hand, MAb's 1FlO, 
TABLE 1 
Reactivity of Serum from 
BALB/c Mice Injected with BSA-glutathione-HgCl 
55 3E8, and 4AlO were two- to three-fold above background 
when assayed with BSA-GSH-HgCI. Background was 
established for both BSA-GSH and BSA-GSH-HgCI by 
measuring their reactivities with a dinitrophenol-specific 
Mouse # BSA-GSH 
1 1.332 
2 0.808 
3 2.382 
4 0.654 
5 0.682 
6 0.453 
7 0.567 
BSA-GSH-HgCl 
1.214 
0.886 
1.505 
0.947 
0.848 
0.756 
0.865 
% Difference 
-8.9 
+9.7 
-36.8 
+44.8 
+24.3 
+66.9 
+52.6 
60 
65 
monoclonal antibody. 
These results suggested that the latter three antibodies 
(IFlO, 3E8, and 4AlO) were specific for either mercuric ions 
alone or for an epitope consisting of both GSH and HgCI2. 
Mab's 4AlO (BN No. 4A10B4, ATCC No. HB 10381) and 
1FlO were subcloned and analyzed further to determine 
whether they would react with mercuric chloride by itself. 
To do so, an inhibition assay was performed in which tenfold 
dilutions of HgCl2 from 1O-
2M to lO-11M were used to 
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inhibit antibody binding to BSA-GSH-HgCl adsorbed to a 
micro titer plate. 
The inhibition assay was conducted as follows. Fifty 
microliters of each concentration of mercuric chloride and 
50 fll of diluted ascites fluid containing the indicated anti-
body were incubated for 30 minutes at room temperature in 
the wells of a microtiter plate containing adsorbed BSA-
glutathione-HgCI. The plates were then washed, and horse-
radish peroxidase-conjugated goat anti-mouse serum was 
added. After incubation and washing as above, ABTS sub-
strate was added, and the A405 was measured after 15 
minutes. Each point represents the average of triplicate 
determinations. Percent inhibition was calculated according 
to the fonowing formula: 
Percent inhibiton = (1 - {[A405 of expo - A405 of neg] .,. 
[A405 of pos. - A405 of neg.]}) x 100 
The results are shown in FIG. 1. 
The binding of both antibodies to adsorbed antigen was 
inhibited by soluble HgCI2 , with 50% inhibition between 
1O-9M and lO-lOM HgCl2 for each. The specificity of the 
inhibition was demonstrated by the inability of the same 
concentrations of mercuric chloride to inhibit the binding of 
an asparagine synthetase-specific monoclonal antibody 
(MAb 3Dll) to asparagine synthetase. These data demon-
strated that reactivity of both antibodies with HgCl2 was 
independent of the presence of either GSH or KLH. 
EXAMPLE II 
Characterization of the Binding Characteristics of 
Monoclonal Antibodies to Mercury 
24 
sample containing the following mixture of metals: 0.2 mg/L 
Hg++, 100 mg/L Ba++, 1 mg/L Cd++, 5 mg/L Cr+++, 5 mg/L 
Pb++, and 5 mg/L Ag+. The sample was diluted to known 
Hg++ concentrations, which were then assayed by ELISA 
5 and compared to results obtained with a standard consisting 
of known concentrations of mercury chloride. 
Briefly, the ELISA was conducted as follows. The QC 
sample and HgCl2 were diluted in water to mercury con-
10 centrations ranging from 0.5 to 200 ppb, then analyzed by 
ELISA. A sample containing the same concentration of all 
other metals as the QC sample except mercury was also 
included. The absorbance obtained in analysis of both water 
without added mercury and the EPA sample without mercury 
15 was 0.263. Each point represents the average absorbance 
obtained from quadruplicate analyses of each sample. See 
FIG. 2. 
The results in FIG. 2 show that significant reactivity was 
obtained with both the EPA sample and the mercury standard 
20 at 2 ppb mercury, and the absorbance for both samples was 
linear up to 20 ppb mercury. Reactivity was due to the 
presence of mercury and not to recognition of one of the 
other metals, since a sample containing all of the metals 
except mercury in the same concentrations as in the EPA 
25 sample gave the same absorbance as water containing no 
mercury. 
30 
The results in FIG. 2 clearly demonstrated that the ELISA 
was capable of sensitive and reproducible detection of 
mercuric ions in water, but they did not reveal how well the 
ELISA correlated with atomic absorption. This is an impor-
tant consideration since cold-vapor atomic absorption is 
currently the method of choice for mercury determination. 
To correlate the results obtained from the two methods, an 
35 atomic absorption mercury reference standard was diluted in 
O.IM HEPES, pH 6.8, to a mercury concentration of 100 
ppb. At this point, two aliquots were removed and diluted to 
the appropriate concentrations for immunoassay in HEPES 
or for atomic absorption in 10% nitric acid. Samples con-
40 taining 0, 2, 4, 5, 10 and 15 ppb mercury were then analyzed 
by both methods. The values shown represent the mean and 
one standard deviation of quadruplicate analyses by immu-
noassay and triplicate analyses by atomic absorption. (See 
FIG. 3.) 
Clearly, antibodies capable of reacting with soluble mer-
curic chloride were identified. It was of interest, then, to 
determine the affinity of the antibodies for mercuric ions, as 
well as to identify other metals to which they might bind. 
The other metal salts used for these analyses included 
barium chloride, cadmium chloride, chromic chloride, cop-
per chloride, ferrous sulfate, gold chloride, mercuric acetate, 
nickel chloride, selenium oxide, silver chloride, and zinc 
chloride. The procedure used to determine the affinity of the 
antibodies for the various metals was the competition ELISA 
described by Friguet et al. (J. Immunol. Methods, 77:305 
45 (1985), which is hereby incorporated by reference. As shown in FIG. 3, the results obtained from the two methods were in close agreement, as indicated by a corre-
lation coefficient of >0.99. In addition, the standard devia-
tion of the immunoassay at most mercury concentrations 
was the same or less than that obtained by atomic absorp-
tion. These results indicated that, under the conditions of this 
assay, quantitation of mercury by ELISA was as precise as 
The results indicated that the disassociation constant of 
MAb 4AIO for HgCl2 was 2.3±0.8xlO-9 M, while that of 
MAb IFIO was 3.7±1.5xlO-9M. Neither antibody bound 
any of the other metals to a detectable extent. However, both 50 
antibodies did have a similar affinity for mercuric acetate, 
with the affinities being 4.l±O.lxlO-9M and 8.2±2.5xlO-9M 
for 4Al 0 and IFIO, respectively. These results indicated that 
the mercuric ion itself was the major epitope recognized by 
these antibodies, regardless of the counterion originally 55 
present in the mercury-containing compound being assayed 
for antibody reactivity. 
Equilibrium dialysis of these monoclonal antibodies with 
uncomplexed glutathione was conducted and it was deter-
mined that the disassociation constant for glutathione was 60 
less than 1O-5M. This data further supports the view that 
these antibodies are immunoreactive with a bare metal 
cation. 
cold-vapor atomic absorption. 
EXAMPLE III 
Production of Monoclonal Antibodies to a Lead 
Cation 
The same strategy used for production of mercury-spe-
cific antibodies employing immunization of mice with a 
metal cation-spacer arm carrier has now been applied to 
generation of antibodies specific for lead. Initially, seven The specificity of the antibodies was further illustrated by 
their ability to detect mercury at concentrations in the 
part-per-billion range, even in the presence of other metals. 
This was demonstrated with an EPA Quality Control (QC) 
65 antibodies were identified that reacted with a carrier protein 
only when lead was present. The ELISA results obtained 
from screening these antibodies are shown below. 
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Hybridoma BSA-GSH BSA-GSH-Pb 
6Bll 0.298 0.954 
8E7 0.055 0.987 
4E8 0.195 0.618, 
3B8 0.212 0.975 
9D3 0.191 0.584 
3B7 0.074 0.710 
lC3 0.161 1.560 
5 
10 
26 
Hybridoma ALAD-Pb ALAD 
14Fll 0.751 0.050 
1.813 0.048 
lC3 1.586 0.030 
These antibodies are specific for an epitope on the ALAD-
lead complex and do not react with epitopes on ALAD 
alone. 
The results shown above clearly demonstrate that the 
same condition that was found for mercury also exists for 
lead, namely that antibodies can be produced that recognize 
lead when it is either in solution or attached to a carrier. 
Several of these antibodies have been assayed for detection 
of lead bound to other carriers, such as other globular 
proteins like ovalbumin, or synthetic polypeptides such as 
poly-L-Iysine. 
A monoclonal antibody specific for lead cation can have 
a disassociation constant for lead cation of less than 1O-9M 
and does not appreciably bind to cadmium, copper, zinc, 
mercury, nickel, and cobalt cations to any appreciable 
extent. 
15 Monoclonal antibody 14Fll could detect lead in solution at 
10 ppm and 1 C3 could detect lead at 1 ppm. Monoclonal 
antibodies reactive with ALAD bound to lead and non-
crossreactive with ALAD alone can be used in an assay to 
To determine whether any of these antibodies would bind 20 
lead in solution, mAb's lC3 and 14Fll (prepared as 
described in Example IV) were used in competition assays 
as described in Example I, to see if lead nitrate in solution 
would inhibit the binding of either mAb to BSA-GSH-Pb++ 
adsorbed to a solid phase. Briefly, 50 J.!l of each concentra- 25 
tion of lead acetate and 50 J.!l of diluted ascites fluid 
containing the indicated antibody were incubated for 30 
minutes at room temperature in the wells of a microtiter 
plate containing adsorbed BSA-glutathione-Iead acetate. 
The plates were then washed, and horseradish peroxidase- 30 
conjugated goat anti-mouse serum was added. After incu-
bation and washing as above, ABTS substrate was added, 
and the A405 was measured after 15 minutes. Each point 
represents the average of quadruplicate determinations. Per-
cent inhibition was determined according to the formula in 35 
the legend to FIG. 1. The results are shown in FIG. 4. 
The binding of both IC3 and 14Fl1 is inhibited by soluble 
lead acetate at concentrations ranging from 10 to 100 ppm, 
with 50% inhibition at approximately 20 ppm and 150 ppm 
for mAb's lC3 and 14Fll, respectively. Thus, these two 40 
antibodies, in addition to reacting with lead attached to a 
carrier, also react with lead in solution. 
EXAMPLE IV 
Preparation of Monoclonal Antibodies Specific for 
Pb-ALAD 
Monoclonal antibodies specific for Pb-ALAD were pre-
45 
50 
pared by standard methods. The amount of ALAD com-
plexed with Pb is a sensitive indicator of the toxicity of the 
lead contamination. ALAD is a naturally occurring enzyme 
whose activity is inhibited by lead contamination and this 55 
inhibition represents one of the toxic effects of lead con-
tamination. The amount of Pb-ALAD present in the blood 
sample is a good indicator of the toxicity level associated 
with the lead contamination of the patient. 
A monoclonal antibody to Pb-ALAD was prepared as 60 
described in Example 1. The resulting hybridomas were 
screened for immunoreactivity with Pb-ALAD and ALAD. 
detect the amount of lead present in a blood sample. 
The immunoreactivity of monoclonal antibodies 14Fll 
and I C3 with bovine ALAD complexed to other metal 
cation was also tes.ted. Bovine ALAD was incubated with 1 
mM of metal cations including Pb, Zn, Cu, Cd, Ni, and Hg, 
for 60 minutes. The bovine-ALAD metal complexes were 
then placed in an ELISA well and assayed for the abilityto 
bind monoclonal antibodies 14Fll and lC3. The results are 
shown below. 
Metal Ion l4Fll 
Pb+2 0.638 
Zn+2 0.060 
Control 0.076 
Pb+2 0.908 
Cu+2 0.102 
Control 0.070 
Cd+2 0.135 
Ni+2 0.126 
Hg+2 0.590 
Control 0.128 
Metal Ion lC3 
Pb+2 0.413 
Hg+2 0.150 
Cd+2 0.064 
Control 0.064 
EXAMPLE V 
Production of Hybridoma Antibodies Specific for 
ALAD 
Since ALAD is one of the earliest and most sensitive 
indicators of exposure to lead, it is a logical target for 
determination of the lead burden in an individual. ALAD is 
a large, multimeric protein, so it will induce formation of 
high affinity, specific monoclonal antibodies. The ALAD-
specific antibody can be used to capture the enzyme from a 
sample of body fluid for subsequent detection oflead bound 
to it. 
The injection regimen for production of antibodies spe-
cific for ALAD was as follows. Bovine liver ALAD was 
mixed with adjuvant and injected intraperitoneally into 
BALB/c mice. Each mouse was given three injections with 
50 flg of ALAD per injection. The presence of ALAD-
A monoclonal antibody, designated 14Fll, has been pro-
duced by injection of Pb-ALAD. The ELISA results when 
this antibody and antibody IC3 (prepared as described in 
Example III) were tested with ALAD-Pb and ALAD alone 
are shown below: 
65 specific antibodies was monitored by an ELISA in which 
200 J.!l of ALAD at a concentration of 5 flg/ml is adsorbed 
to the wells of 96-well polystyrene microtiter plates by 
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incubation at room temperature for 2 hours. Two hundred 
microliters of 1 % polyvinyl alcohol in PBS was added to 
each well and incubated at room temperature for one hour to 
block the nonspecific protein-binding sites. Fourfold dilu-
tions of each serum sample were prepared, and 100 J.!l of 5 
each was added to duplicate wells of a microtiter plate. After 
incubation at room temperature for 60 minutes, the plates 
were washed three times with ELISA wash (PBS with 0.1 % 
Nonidet P-40). One hundred microliters of goat anti-mouse 
serum conjugated to horseradish peroxidase was added, and 10 
the plates were incubated and washed as above. Peroxidase 
substrate (ABTS) was then added, and the absorbance of 
each well at 405 nm was measured after incubation for 15 
minutes at room temperature. Controls consist of assaying 
each serum dilution against bovine serum albumin instead of 
ALAD to determine their nonspecific reactivity, and assay- 15 
ing serum from a non-injected mouse against ALAD. Three 
mice injected as described above show an ELISA titer of 
>10,000 against ALAD and <1,000 against BSA. 
28 
Hybridoma ALAD ALAD-Pb 
llB12 0.877 0.666 
These results demonstrate that mAb llB12 reacted with 
ALAD regardless of the presence of lead. 
To assay for antibody binding to human erythrocyte 
ALAD, inhibition of the enzyme activity in the presence of 
the monoclonal antibody was measured. The appropriate 
amount of each antibody was pre-determined by titration in 
a solid-phase ELISA and added to the wells of a microliter 
plate. After antibody adsorption to the plate, 100 J.!l of a 
lysate from washed human erythrocytes was added. The 
plates were incubated at room temperature for 30 minutes, 
washed, and ALAD activity was determined by a modifi-
cation of the procedure of Tsukamoto et al., BBA, 
570: 167-168 (1979). Briefly, 100 J.!l of Tris-acetate, pH 7.1, 
containing 4 mM o-aminolevulinic acid hydrochloride was The spleen from one of these mice was used for fusion 
with SP2IO myeloma cells for production of hybridomas, 
according to standard methodology, as described by J. 
Liddell et al., in A Practical Guide to Monoclonal Antibod-
ies, pp. 67-88 (1992). Four monoclonal antibodies were 
obtained from the fusion. The ELISA results from initial 
20 added and the plates were incubated at 37° C. for various 
times. At the appropriate time, 100 J.!l of Ehrlich's reagent 
was added, and the reaction mixture was incubated for 30 
minutes at room temperature to allow for color develop-
25 
screening of these antibodies against ALAD and BSA-GSH 
are shown below. BSA-GSH was included to identify 
polyreactive antibodies. 
Hybridoma ALAD BSA-GSH SIN' 30 
lC6 1.466 0.128 11.5 
IOG4 0.796 0.109 7.3 
llB12 1.938 0.213 9.1 
12F8 1.417 0.131 10.8 
----------------------------------------- 35 
'SIN = Signal· to-Noise Ratio. This was obtained by dividing the adsorhance 
with ALAD by that obtained from assay against BSA-GSH. 
The results shown above indicate that these four antibod-
ment. The absorbance at 540 nm was then determined to 
measure porphobilinogen synthesis. The results obtained 
after incubation of the reaction mixture for 48 hours are 
shown below. 
Hybridoma Enzyme Substrate A450 
llB12 + + 2.066 
+ .065 
+ .026 
.027 
The numbers represent the absorbance at 540 nm in the 
experimental samples, which contained the reaction mixture 
described above. The controls consisted of the absorbance at 
540 nm obtained with a sample incubated for the same 
40 length of time in the absence of monoclonal antibody, or in 
the absence of enzyme, or in the absence of substrate. The 
results indicated that llB12 was suited for trapping enzy-
matically active ALAD in human erythrocyte Iysates. 
ies were specific for ALAD, as indicated by their preferential 
reactivity with the specific antigen (ALAD) over a non-
specific one (BSA-GSH). However, the ALAD-specific anti-
bodies were induced by injection of bovine liver ALAD and 
were identified by reactivity with the same immunogen 
adsorbed to the wells of a microtiter plate. It was possible, 
then, that the antibodies were specific for a species-specific 
epitope accessible only when ALAD was adsorbed to a 
microtiter plate. Adsorption of proteins to a solid support can 
cause denaturation, so that any monoclonal antibody 
detected in this assay might be specific for a denatured 
epitope and would not react with the native enzyme. In 50 
addition to recognizing native ALAD in an erythrocyte 
lysate, an ALAD-specific antibody preferably fulfilled two 
additional requirements: first, it had to recognize an ALAD 
epitope whose ability to react with the antibody would not 
Monoclonal antibodies that react only with lead-ALAD, 
45 as described in Example IV, and not with ALAD can also be 
selected and used to provide for greater sensitivity. 
be influenced by the presence of lead; and, second, it had to 55 
bind a sufficient amount of ALAD to allow immunological 
detection of any attached lead. The ability of each of the 
ALAD-specific antibodies shown above to fulfill these 
requirements was examined. 
To determine whether any of the antibodies would bind 60 
ALAD with lead attached, ALAD was adsorbed to the wells, 
after which Pb was added to some wells but not to others. 
MAb I1BI2 was then tested for reactivity withALAD in the 
presence and absence of lead. This antibody was selected 
because it consistently reacted more strongly with ALAD in 65 
routine ELISA's than the other antibodies. The results are 
shown below. 
EXAMPLE VI 
Development of an Immunoassay for the Detection 
of Metallic Cation in a Sample of Body Fluid 
A method for detecting a metallic cation in a sample of 
body fluid was developed by detecting the amount of the 
metallic cation bound to a naturally occurring protein such 
as ALAD present in the sample of body fluid. Two antibod-
ies specific for ALAD, prepared as described in Example IV, 
were used to determine whether lead could be detected in 
blood samples in the assay design envisioned for the kit 
format. The blood samples used for this experiment were 
bovine blood samples from cattle exposed to lead, which 
were obtained from the Center for Disease Control. 
MAb llB12 (ALAD-specific) was adsorbed to the weJls 
of a microtiter plated as described above. One hundred 
microliters of extract containing ALAD from two blood 
samples from cows exposed to lead. The two samples were 
designated BES90, which contained lead at 8.5 Ilg/dl and 
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BE890, which contained lead at a concentration of 15 flg/dl. 
After incubation for 30 minutes in the well, the extract was 
removed, the plates were washed, and 100 f.1l of a I: 1000 
dilution of ascites fluid containing mAb 14Fll (lead-spe-
cific) or IOG4 (ALAD-specific) was added. After incubation 5 
for 60 minutes, a peroxidase labelled anti-IgM antibody was 
added to each well. After incubation and washing as above, 
100 f.1l of ABTS was added, and the absorbance of 405 nm 
Sample 
I 
2 
3 
IX PBS 
30 
Adsorbance Blood-Pb 
1.291 55 
0.225 4 
0.244 2 
0.093 0 
was measured. The results are shown below. There is a good positive correlation between adsorbance 
10 and blood-lead values. Thus, immunoassays for lead bound 
1004 
Blood Sample Absorbance 
PBS 0.195 
BE590 1.452 
BE890 1.451 
14Fll 
Absorbance 
1.091 
1.195 
1.405 
15 
to hemoglobin can be used as an indication of a patient's 
lead burden. 
EXAMPLE VIII 
Detecting Lead Bound to Serum Albumin 
The numbers represent the absorbance at 405 nm of the 
samples in the ELISA done as described above. The sample 
designated as PBS served as a negative control and con-
tained only PBS instead of extract from a blood sample. 
Lead binds to many of the proteins found in blood cells 
and plasma. Serum albumin, a major constituent of serum, 
20 is one of the proteins that also binds lead. An immunoassay 
that uses antibodies to serum albumin and antibodies to lead 
can specifically detect lead bound to serum albumin. As can be seen, Pb was detected in the contaminated 
samples using the immunoassay in accordance with the 
invention. These results are extremely important because 
they indicate that the approach described for detecting lead 25 
bound to ALAD will do so in a "real world" blood sample. 
In spite of the seeming lack of sensitivity of mAb 14Fll for 
binding to soluble lead (FIG. 4), it is sufficiently sensitive to 
be used for detecting lead bound to ALAD. As previously 
mentioned, it could be that, since this mAb was induced by 30 
Pb-ALAD, it will react with soluble lead, but preferably 
reacts with lead bound to ALAD. 
Antibodies to serum albumin are generated easily using 
standard laboratory animals, and also are available commer-
cially. These antibodies may be polyclonal or monoclonal, 
and can be very specific, e.g. for rare variants or for specific 
epitopes or for one species, or can be less specific and more 
crossreactive. Antibodies to lead have been generated as 
described in Example III. 
Immunoassays to detect lead bound to serum albumin 
have been done. First, antibodies to serum albumin (Sigma 
Chemical Co., St. Louis, Mo.) were adsorbed to a solid 
substrate. Next, agents to block non-specific adsorption were 
incubated on the solid substrate. Third, samples of lead 
EXAMPLE VII 
Detecting Lead Bound to Hemoglobin 
Lead binds to many of the proteins found in blood cells 
and plasma. Hemoglobin, a major constituent of erythro-
cytes, is one of the proteins that binds lead. Gercken et al., 
Anal. Chern., 63:283-287 (1991). An immunoassay that uses 
antibodies to hemoglobin and antibodies to lead might 
specifically detect lead or mercury bound to hemoglobin. 
35 contaminated human serum were incubated on the solid 
substrate. Fourth, a monoclonal antibody specific for lead 
(l4Fll) was incubated on the solid substrate. This was 
followed by incubation with an antibody reporter enzyme 
conjugated antibodies that bind to the lead antibodies con-
40 jugated to a reporter enzyme, and then followed by a 
chromogenic enzyme substrate. 
Antibodies to hemoglobin are generated easily using 
standard laboratory animals, and also are available commer-
cially. These antibodies may be polyclonal or monoclonal, 
and can be very specific, e.g. for rare variants or for specific 
subunits or for one species, or can be less specific and more 
crossreactive. Antibodies to lead have also been generated as 
described in Example III. 
45 
50 
The results show that lead bound to serum albumin was 
detected in an immunoassay using two different antibodies 
as described in Example VI. 
Sample Adsorbance Blood-Pb 
I 1.251 35 
2 0.390 20 
3 0.442 16 
4 0.400 12 
5 0.352 4 
IX PBS 0.093 0 
This immunoassay is useful to qualitatively screen for the 
55 presence or absence of Pb contamination of a blood sample. 
Immunoassays to detect lead bound to hemoglobin have 
been done. First, monoclonal antibodies to hemoglobin 
(obtained from Medix Biotech, Inc.) were adsorbed to a 
solid substrate. Next, agents to block non-specific adsorption 
were incubated on the solid substrate. Third, samples of 
lysed erythrocytes from lead contaminated human blood 
were incubated on the solid substrate. Fourth, a monoclonal 
antibody specific for lead (l4FII) was incubated on the solid 60 
substrate. This was followed by a reporter enzyme conju-
gated with a chromogenic enzyme substrate. The amount of 
lead present in the original sample should positively corre-
late with the amount of color produced. 
The results show that lead bound to hemoglobin was 65 
detected using an immunoassay employing two different 
antibodies as described in Example VI: 
EXAMPLE IX 
Comparison of an Acute vs. Chronic Lead 
Exposure on the Detection of Pb Bound to ALAD 
and Hemoglobin 
Naturally occurring proteins that bind to lead can also 
serve as indicators of an acute vs. chronic exposure to lead. 
For example, it is known that inhibition of ALAD activity 
with Pb+2 after a single exposure in mice occurs as early as 
3 hours and peaks in 24 hours and then the ALAD activity 
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returns to normal activity within 2-4 days post-exposure. 
Schlick et aI., Areh. Toxieol., 43 :213 (1980).Binding of Pb+2 
to hemoglobin may proceed more slowly and Pb may be 
retained by hemoglobin for a longer period of time. An 
immunoassay employing a comparison of lead bound to 5 
ALAD and to hemoglobin may allow diagnosis of an acute 
vs. chronic exposure to Pb+2. 
Rabbits will be exposed to an acute and chronic Pb 
exposure in their drinking water and Pb concentration bound 
to ALAD and hemoglobin determined over time. Lead 10 
acetate will be administered to the animals in water bottles. 
Sodium acetate will be fed to control animals. The treatment 
groups will be as follows: 
Treatment 1 (2 to 4 rabbits) 
Treatment with 10 mg Pb/kg/day for 5 days, followed by 15 
control treatment for 5 weeks. 
Treatment 2 (2 to 4 rabbits) 
32 
dodecylsulfate), 10 ml glycerol, 5 ml ~-mercaptoethanol, 
and distilled H20 to 25 mls (pH=6.8). Each sample con-
tained a metal containing red cell lysate (varying amounts), 
10 fll of 4 X sample buffer and 40 f.1l distilled H20. The 
samples were mixed vigorously and boiled for 5 minutes. 
Samples were loaded onto Tris/glycine SDS polyacrylamide 
gels and the gels were electrophoresed under standard 
conditions as described in Antibodies: A Laboratory 
Manual, cited supra. 
Once electrophoresis was completed, the proteins in the 
samples were transferred to nitrocellulose membranes by 
either simple diffusion, vacuum assisted solvent flow, or 
electrophoretic elution. The preferred method is electro-
phoretic elution by semi-dry transfer. With the semi-dry 
transfer method, the gel nitrocellulose membrane sandwich 
was placed between absorbent paper soaked in transfer 
buffer. The transfer buffer contained 48 mM ofTris base, 2M 
glycine, 3% methanol, and distilled water. On the bottom 
plate of the gel transfer apparatus (the anode), the sandwich 
Control treatment for 5 weeks followed by 5 days of 10 
mg Pb/kg/day. 
Treatment 3 (2 to 4 rabbits) 
Treatment of rabbits with 1 mg Pb/kg/day for 6 weeks. 
Treatment 4 (2 to 4 rabbits) 
Control treatment for 6 weeks. 
20 for electroelution was assembled as follows: a sponge, 3 
layers of absorbent paper soaked in transfer buffer, the 
polyacrylamide gel wetted with H20, nitrocellulose mem-
brane soaked in water, and 3 layers of absorbent paper 
Blood samples will be taken on the first day of treatment 
every 3 hours and analyzed for Pb bound to ALAD, as 25 
described in Example VI, and for Pb bound to hemoglobin, 
as described in Example VII. Thereafter blood samples will 
be taken regularly, typically once a week or less, and 
analyzed similarly. It is likely that the ratio of the amount of 
Pb detected bound to ALAD compared to the amount bound 30 
to hemoglobin after an acute exposure will be higher than 
the ratio of the amount of Pb detected bound to ALAD 
compared to the amount bound to hemoglobin after a 
chronic exposure. It is expected that the amount of lead 
bound to ALAD will be higher than the amount of lead 35 
bound to hemoglobin after an acute exposure. It is expected 
that the amount of lead bound to ALAD will decrease over 
time in a chronic exposure as compared to an acute expo-
sure. 
soaked in transfer buffer, sponge, and the upper electrode 
(cathode) on top of the stack. The electrodes were connected 
and current was applied for 40 minutes at 100 V. 
Once transferred to the nitrocellulose membrane, the 
proteins were reacted with specific antibodies. Before the 
membrane was treated with the antibodies, however, non-
specific binding of the antibody was blocked by treating the 
membrane with a protein or detergent solution, such as 
non-fat dry milk. The membranes were then incubated with 
monoclonal antibodies specific for the metallic cations. 
EXAMPLE X 
Method for Identifying Naturally Occurring 
Polypeptides That Bind Metallic Cations 
Each membrane was removed from the blocking solution 
and washed twice for 30 minutes each in PBS. The mono-
clonal antibody 14FII specific for lead was incubated with 
each of the membranes in 1 % polyvinyl acetate, 5% bovine 
calf serum, 0.01% sodium azide in phosphate buffered saline 
in a shallow tray. Antibody concentration should be between 
40 1-50 flg/ml. The membranes were incubated for at least 2 
hours at room temperature with agitation. After incubation, 
the membrane is washed twice with PBS and twice with 
ELISA wash (PBS with 0.1 % Tritonx-100). 
45 The membrane was then treated with a enzyme labelled 
secondary antibody. The secondary antibody is a goat anti-
mouse IgM antibody labelled with horseradish peroxidase. 
The membrane and the secondary antibody were incubated 
for 1.5 hours at room temperature with agitation. The gel 
Naturally occurring polypeptides beside ALAD are 
capable of binding to metallic cations and can be used to 
detect the presence of and/or to quantitative the amount of 
a metallic cation in a body fluid. A method for identifying 
other naturally occurring polypeptides that bind to metallic 
cations and/or to identify whether the polypeptides bind 
metallic cations at a low enough concentration to be a 
sensitive indicator of metallic cation contamination includes 
using a Western blot technique. The Western blot technique 
50 was then rinsed twice for 30 minutes with PBS and twice for 
30 minutes with ELISA wash. To develop the membrane, the 
membrane was incubated with the peroxidase substrate TM 
Blue (TSI, Inc.). 
is carricd out according to standard methods, as described in 55 
Antibodies: A Laboratory Manual, Harlow & Lane, editors, 
Cold Spring Harbor, Cold Spring, N.Y. at pages 571-610 
(1988). 
The results are shown in FIG. 5. Lead bound to hemo-
globin was detected as shown in Lanes 3, 4 and 5 in blood 
samples containing as low as 5 flg Pb/dl. The hemoglobin 
band is seen at 64,000 daltons. Other bands visualized 
represent carbonic anhydrase (29,000), albumin (66,000), 
transferrins (76,000-81,000), and hemocyanin (70,000). 
60 Lane 2 represents a Western blot of a lead depleted red cell 
lysate sample. These results show that naturally occurring 
metallic cation containing proteins can be readily identified 
using the metallic cation specific antibodies of the invention 
and Western blot. 
First, blood samples not thought to be heavily contami-
nated with exogenous metallic cations, such as lead "or 
mercury or methylmercury, were treated with a lysing agent 
such as Triton X-IOO. The lysing agent acts to lyse cells, 
including red cells present in the blood sample. The samples 
run on Western blots had known concentrations of blood 
lead determined by anodic stripping voltametry ranging 65 
from 4 flgldl to 55 flg/dl. The samples were then mixed with 
4 X sample buffer of 76.0 mg Tris base, 2 gm SDS (sodium 
Bands identified by Western blot can be identified by their 
molecular weights, and these bands can be eluted from 
companion gels for further characterization and identifica-
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tion by methods known to those of skill in the art. For 
example, a naturally occuning polypeptide binding metallic 
cations can be identified by using monoclonal antibodies 
specific for known blood polypeptides. Membranes run 
under the same conditions can be incubated with mono- 5 
clonal antibodies specific for human serum albumin or 
hemoglobin or other known blood proteins. 
By comparing the Western blot results for blood samples 
mixed with different concentrations of the metallic cations, 
those polypeptides detected as binding lead or mercury at 10 
very low concentrations (less than about 25 Ilg!dl) can be 
considered sensitive enough to use in a immunoassay for 
metallic cations. It can also be determined if the binding of 
the metallic cation by the polypeptide is related linearly to 
the amount of metallic cation initially added to the sample. 15 
EXAMPLE XI 
Formation of Monoclonal Antibodies to Glutathione 
or Glutathione Metallic Cation Complex 
20 
34 
readily apparent to those skilled in the art, and this appli-
cation is intended to cover any adaptations or variations 
thereof. 
What is claimed is: 
1. A method for detecting a metallic cation in a sample of 
a body fluid of an animal, which comprises: 
contacting an effective amount of a first antibody specific 
for a naturally occuning polypeptide or a functional 
portion of the polypeptide with the sample of body fluid 
containing the metallic cation to form a first antigen-
antibody complex, wherein the naturally occurring 
polypeptide can bind the metallic cation; 
adding an effective amount of a second antibody specific 
for the metallic cation to the first antigen-antibody 
complex to form a second antigen-antibody complex; 
and 
determining the amount of the metallic cation in the 
sample of the body fluid by detecting the amount of the 
second antigen-antibody complex. 
Monoclonal antibodies specific for glutathione or glu-
tathione-mercury complex were obtained by following the 
immunization procedure described in Example I. As shown 
in Table 2 on page 35, monoclonal antibodies reactive with 
both glutathione HgCI and glutathione complexed to the 
carrier bovine serum albumin were isolated and identified in 
2. A method according to claim 1, wherein the second 
antibody specific for the metallic cation is a monoclonal 
antibody specific for metallic cation is selected from the 
group consisting of transition metals, Group IlIa metal! 
metalloids, and Group IVa metal/metalloids. 
25 3. The method according to claim 2, wherein the metallic 
cation is lead. 
an ELISA assay. Monoclonal antibodies IHll, 2A9 was 
specific for both BAS-GSH-HgCI and BSA-GSH. Mono-
clonal antibodies 3AI2 and 3H9 bound to BSA-GSH pref-
erentially, rather than to the BAS-GSH-HgCI. The mono-
clonal antibodies can be further characterized to ensure that 
they are specific for the glutathione-mercury complex or 
glutathione and not for epitopes on BSA. 
4. A method according to claim 1, wherein the second 
antibody specific for the metallic cation does not substan-
tially cross-react with other metallic cations. 
30 5. A method according to claim 1, wherein the second 
antibody specific for the metallic cation has a dissociation 
constant of about 10-4 to 10-13. 
Monoclonal antibodies IHII and 2A9, 3AI2 and 3H9 can 
be assayed in an ELISA for the ability to bind to glutathione 
alone or glutathione-mercury complex. Briefly, glutathione 
6. A method according to claim 1, wherein the second 
antibody specific for the metallic cation is labelled with an 
35 enzyme. 
or glutathione mercury complex can be incubated in the 
wells of an ELISA plate under conditions that allow the 40 
glutathione or glutathione complex to bind to the plate. The 
ELISA plate is then washed and incubated with either IHII, 
2A9, 3A12, or 3H9 for 2 hours at room temperature. After 
incubation, the plate was washed and incubated with goat 
anti-mouse antibody conjugated with alkaline phosphatase. 45 
After incubation, paranitrophenyl phosphate is added and 
A405 of each well measured after incubation at room 
temperature of 15-30 minutes. The specificity of each of 
these monoclonal antibodies for either glutathione or glu-
tathione mercury complex can be confirmed by detecting 50 
immunoreactivity in the ELISA assay. 
Monoclonal antibodies specific for glutathione or glu-
tathione mercury cations can serve as the antibody specific 
for a naturally occuning polypeptide that binds metallic 
cation or the antibody specific for an epitope on a metallic 55 
cation-naturally occuning polypeptide complex. If the anti-
body is specific for both glutathione and glutathione mer-
cury complex, it can be used as an antibody specific for a 
naturally occurring polypeptide that binds metallic cation. If 
the antibody is only specific for glutathione mercury com- 60 
plex, then it can be used for an antibody specific for an 
epitope on a metallic cation-naturally occurring polypeptide 
complex. 
All patents and publications cited herein are hereby 
incorporated by reference. While the present invention has 65 
been described in connection with the preferred embodiment 
thereof, it will be understood many modifications will be 
7. A method for determining whether an animal has been 
exposed acutely or chronically to a metallic cation, which 
comprises: 
detecting the amount of the metallic cation bound to a first 
type of naturally occuning polypeptide that binds the 
metallic cation, wherein the first type of naturally 
occuning polypeptide can bind the metallic cation upon 
an acute exposure to the metallic cation; 
detecting the amount of the metallic cation bound to one 
or more second type of naturally occuning polypeptide 
that can bind the metallic cation; wherein the second 
type of naturally occuning polypeptide can bind the 
metallic cation after a chronic exposure to the metallic 
cation and 
comparing the amount of the metallic cation bound to the 
first type of naturally occuning polypeptide to tne 
amount of metallic cation bound to one or more second 
type of naturally occuning polypeptide to determine 
whether the exposure to the metallic cation is acute or 
chronic. 
8. Tile method according to claim 7, wherein the first type 
of naturally occuning polypeptide is ALAD and the metallic 
cation is lead. 
9. The method according to claim 7, wherein the second 
type of naturally occuning polypeptide is hemoglobin and 
the metallic cation is lead. 
10.-The method according to claim 7, wherein the step of 
detecting the amount of the metallic cation bound to a first 
type of naturally occuning polypeptide includes contacting 
an effective amount of a first antibody specific for the first 
type of naturally occurring polypeptide with the sample of 
5,532,136 
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body fluid containing the metallic cation to fonn a first 
antigen-antibody complex; 
adding an effective amount of a second antibody specific 
for an epitope on a metallic cation-first type of naturally 
occurring polypeptide complex to the first antigen-
antibody complex to form a second antigen-antibody 
complex, wherein the second antibody does not sub-
stantially cross-react with an epitope found on the first 
type of naturally occurring polypeptide alone; and 
determining the amount of the metallic cation in the body 
fluid by detecting the amount of the second antigen-
antibody complex. 
36 
13. A kit according to claim 11, wherein the second 
antibody is labeled by a detectable agent. 
14. A kit according to claim 11, wherein the first antibody 
is specific for an epitope of a metallic cation-naturally 
5 occurring polypeptide complex. 
15. A kit according to claim 14, wherein the first antibody 
is specific for an epitope not found on the naturally occurring 
polypeptide alone. 
16. A kit according to claim 15, wherein the first antibody 
10 does not substantially cross-react with an epitope found in 
the naturally occurring polypeptide alone. 
17. A kit according to claim 11, wherein the metallic 
cation is a lead cation or a mercury cation. 11. A kit for detecting a metallic cation in a sample of a 
body fluid from an animal, which comprises: 
15 
a first antibody specific for a naturally occurring polypep-
18. A kit according to claim 11, wherein the first antibody 
is specific for a naturally occurring polypeptide selected 
from the group consisting of I'i-arninolevulinic acid dehy-
dratase (ALAD), hemoglobin, human serum albumin, trans-
ferrin, glutathione, and protein kinase C. 
tide, wherein the polypeptide can bind to the metallic 
cation; and 
a second antibody specific for the metallic cation. 
12. A kit according to claim 11, wherein the first antibody 
is immobilized on a substrate. 
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